

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|--|--|
| (51) International Patent Classification ⁶ : C07C 315/00 | | A2 | (11) International Publication Number: WO 99/47497 |
| | | (43) International Publication Date: 23 September 1999 (23.09.99) | |
| (21) International Application Number: PCT/CA99/00212 | | (81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | |
| (22) International Filing Date: 12 March 1999 (12.03.99) | | | |
| (30) Priority Data: 60/077,990 13 March 1998 (13.03.98) US 9815856.1 21 July 1998 (21.07.98) GB | | | |
| (71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). | | Published Without international search report and to be republished upon receipt of that report. | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): GAREAU, Yves [CA/CA]; (CA). LABELLE, Marc [CA/CA]; (CA). JUTEAU, Helene [CA/CA]; (CA). GALLANT, Michel [CA/CA]; (CA). LACHANCE, Nicolas [CA/CA]; (CA). BELLEY, Michel [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). | | | |
| (74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA). | | | |

(54) Title: CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT



(57) Abstract

Compounds of formula (I), as well as pharmaceutically acceptable salts, hydrates and esters thereof, are disclosed. The compounds are useful for treating or preventing prostaglandin mediated diseases. Pharmaceutical compositions containing such compounds and methods of treatment are also included.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakhstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

5

CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

BACKGROUND OF THE INVENTION

10 The present invention relates to compounds which are
useful for treating or preventing prostaglandin mediated diseases,
methods of treatment and pharmaceutical compositions containing
such compounds. The compounds are structurally different from
conventional NSAIDs and opiates, and are antagonists of the pain and
15 inflammatory effects of E-type prostaglandins.

Two review articles describe the characterization and
therapeutic relevance of the prostanoid receptors as well as the most
commonly used selective agonists and antagonists: *Eicosanoids: From
Biotechnology to Therapeutic Applications*, Folco, Samuelsson, Macclouf,
20 and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and
Journal of Lipid Mediators and Cell Signalling, 1996, 14, 83-87. An
article from *The British Journal of Pharmacology* (1994, 112, 735-740)
suggests that Prostaglandin E₂ (PGE₂) exerts allodynia through the EP₁
receptor subtype and hyperalgesia through EP₂ and EP₃ receptors in the
25 mouse spinal cord.


Thus, selective prostaglandin ligands, agonists or antagonists,
depending on which prostaglandin E receptor subtype is being
considered, have anti-inflammatory, antipyretic and analgesic
properties, and in addition inhibit hormone-induced uterine
30 contractions. Moreover, the compounds have anti-cancer effects.

The compounds have a reduced potential for
gastrointestinal toxicity, a reduced potential for renal side effects, a
reduced effect on bleeding times and a lessened ability to induce asthma
attacks in aspirin-sensitive asthmatic subjects.

35

5 SUMMARY OF THE INVENTION

The present invention relates to compounds represented by formula I:



I

10 as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:

HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

15 A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-, -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂- or -CR⁷=CR⁷-, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;

20 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;

Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸-;

25 B represents -(C(R¹⁸)₂)_p-Y-(C(R¹⁸)₂)_q-

wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸=CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

30 R¹ R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, -(C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;

35 each R⁴ is independently H, F, CF₃ or lower alkyl,

5 or two R^4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, $S(O)_n$ or $N(O)_m$;

each R^5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , lower alkyl-HET, lower alkenyl-HET or $-(C(R^{18})_2)_pPh(R^{11})_0-$
10 2;

each R^6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF_3 , Ph, Bn and when two R^6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, $S(O)_n$ or
15 $N(O)_m$;

each R^7 is independently H, F, CF_3 or lower alkyl, and when two R^7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, $S(O)_n$ and $N(O)_m$;

20 each R^8 represents H or R^5 ;

each R^9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;

each R^{10} is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , $Ph(R^{11})_0-3$, $CH_2Ph(R^{11})_0-3$ or $N(R^6)_2$;

25 each R^{11} is independently lower alkyl, SR^{20} , OR^{20} , $N(R^6)_2$, $-CO_2R^{12}$, $-CON(R^6)_2$, $-C(O)R^{12}$, CN, CF_3 , NO_2 or halogen;

each R^{12} is independently H, lower alkyl or benzyl;

each R^{13} is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, $N(R^6)_2$, CO_2R^{12} , CN, CF_3 or NO_2 ;

30 R^{14} and R^{15} are independently lower alkyl, halogen, CF_3 , OR^{16} , $S(O)_nR^{16}$ or $C(R^{16})_2OR^{17}$;

each R^{16} is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF_3 ;

each R^{17} is independently H, lower alkyl or Bn;

35 each R^{18} is independently H, F or lower alkyl, and when two R^{18} groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, $S(O)_n$ or N;

- 5 each R^{19} is lower alkyl, lower alkenyl, lower alkynyl, CF_3 ,
HET(Ra)₄₋₉, lower alkyl-HET(Ra)₄₋₉ or lower alkenyl-HET(Ra)₄₋₉;
 each R^{20} is independently H, lower alkyl, lower alkenyl,
lower alkynyl, CF_3 or $Ph(R^{19})_2$
and
- 10 each Ra is independently selected from the group consisting
of:
H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,
C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino,
di-C₁₋₆alkylamino, CF_3 , C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆
15 6alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl,
said alkyl, alkenyl, alkynyl and the alkyl portions of
alkylamino and dialkylamino being optionally substituted with 1-3 of:
hydroxy, halo, aryl, C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, CF_3 ,
C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl,
20 CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆alkyl and N(C₁₋₆alkyl)₂.
- Pharmaceutical compositions are also included which are
comprised of a compound of formula I in combination with a
pharmaceutically acceptable carrier.
- A method of treating or preventing a prostaglandin
25 mediated disease is also included which is comprised of administering
to a mammalian patient in need thereof, a compound of formula I in an
amount which is effective for treating or preventing a prostaglandin
mediated disease.

30 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to carboxylic acids and
acylsulfonamides, which are ligands at prostaglandin receptors, as well
as a method for treating or preventing a prostaglandin mediated disease
comprising administering to a patient in need of such a treatment of an
35 amount of compound of Formula I which is effective for treating or
preventing a prostaglandin mediated disease.

The invention described in this patent application is
described using the following definitions unless otherwise indicated.

5 HET represents a 5-12 membered aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N wherein n is 0, 1 or 2. HET may be substituted with up to three substituents on the aromatic ring system, R¹, R² and R³. "Aromatic ring systems" as used herein includes aryl and heteroaryl groups such as benzene,
10 naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole.

15 HET² is a subset of HET and represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl.

 Aryl refers to aromatic 6-10 membered groups having 1-2 rings and alternating (resonating) double bonds. Examples include
20 phenyl, biphenyl and naphthyl.

 Heteroaryl refers to aromatic 5-12 membered groups having alternating (resonating) double bonds and containing from 1-4 heteroatoms selected from O, S(O)_n and N. Examples include the following: : quinoline, furan, benzofuran, thiophene, benzothiophene,
25 thiazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, oxazole, indole, isoindole, pyridine, isoquinoline, imidazole, thiazole, triazole, 1,3-methylene dioxobenzene, pyrrole and naphthyridine,

 Heterocyclyl refers to non-aromatic 5-12 membered cyclic groups having 1-4 heteroatoms selected from O, S(O)_n and N. Examples
30 of heterocyclic groups are piperidine, piperazine, pyrrolidine, tetrahydrofuran, tetrahydropyran and morpholine.

 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are
35 attached to the aryl or heteroaryl group X in positions which are ortho relative to each other. Examples are selected from the group consisting of: phenyl, naphthyl, biphenyl, quinoline, furan, benzofuran, pyridyl, pyrrole, thiophene, benzothiophene, thiazole, benzothiazole, 1,2,5-

5 thiadiazole, triazole, 1,2-methylenedioxybenzene, thienopyridine, oxazole and indole.

The terms alkyl, alkenyl, and alkynyl mean linear, branched, and cyclic structures and combinations thereof.

10 "Lower alkyl" means alkyl groups of from 1 to 7 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, cyclopropyl, isopropyl, butyl, s- and t-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, and the like. When propyl and butyl are recited without the isomeric form being specified, these include all isomers thereof.

15 "Lower alkenyl" means alkenyl groups of 2 to 7 carbon atoms. Examples of lower alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, cyclopropen-1-yl, cyclohexen-3-yl and the like. When cis or trans is not specified, both are intended in pure form as well as in
20 the form of a mixture of isomers.

"Lower alkynyl" means alkynyl groups of 2 to 7 carbon atoms. Examples of lower alkynyl groups include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl, 2-(cyclopropyl)ethenyl, 3-(cyclobutyl)-1-propynyl and the like.

25 Halogen (halo) includes F, Cl, Br and I.

The following abbreviations have the indicated meanings:


| | | | |
|----|-------------------|---|--------------------------------------|
| | AIBN | = | 2,2'-azobisisobutyronitrile |
| | B.P. | = | benzoyl peroxide |
| | Bn | = | benzyl |
| 30 | CCl ₄ | = | carbon tetrachloride |
| | D | = | -O(CH ₂) ₃ O- |
| | DAST | = | diethylamine sulfur trifluoride |
| | DCC | = | dicyclohexyl carbodiimide |
| | DCI | = | 1-(3-dimethylaminopropyl)-3-ethyl |
| 35 | | | carbodiimide |
| | DEAD | = | diethyl azodicarboxylate |
| | DIBAL | = | diisobutyl aluminum hydride |
| | DME | = | ethylene glycol dimethylether |
| | DMAP | = | 4-(dimethylamino)pyridine |
| 40 | DMF | = | N,N-dimethylformamide |
| | DMSO | = | dimethyl sulfoxide |
| | Et ₃ N | = | triethylamine |
| | LDA | = | lithium diisopropylamide |

| | | | |
|----|----------------------------------|---|--|
| 5 | m-CPBA | = | metachloroperbenzoic acid |
| | NBS | = | N-bromosuccinimide |
| | NSAID | = | non-steroidal anti-inflammatory drug |
| | PCC | = | pyridinium chlorochromate |
| | PDC | = | pyridinium dichromate |
| 10 | Ph | = | phenyl |
| | 1,2-Ph | = | 1,2-benzenediyl |
| | Pyr | = | pyridinediyl |
| | Qn | = | 7-chloroquinolin-2-yl |
| | Rs | = | -CH ₂ SCH ₂ CH ₂ Ph |
| 15 | r.t. | = | room temperature |
| | rac. | = | racemic |
| | THF | = | tetrahydrofuran |
| | THP | = | tetrahydropyran-2-yl |
| 20 | <u>Alkyl group abbreviations</u> | | |
| | Me | = | methyl |
| | Et | = | ethyl |
| | n-Pr | = | normal propyl |
| | i-Pr | = | isopropyl |
| 25 | n-Bu | = | normal butyl |
| | i-Bu | = | isobutyl |
| | s-Bu | = | secondary butyl |
| | t-Bu | = | tertiary butyl |
| | c-Pr | = | cyclopropyl |
| 30 | c-Bu | = | cyclobutyl |
| | c-Pen | = | cyclopentyl |
| | c-Hex | = | cyclohexyl |

It is intended that the definition of any substituent (e.g., R⁵, R⁶, etc.) in a particular molecule be independent of its definition elsewhere in the molecule. Thus, -N(R⁶)₂ represents -NHH, -NHCH₃, -NHC₆H₅, and the like.

In one aspect of the invention, the invention relates to a compound represented by formula I:

40



I

as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:

5 HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-,
 10 -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂ or CR⁷=CR⁷, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;

X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and
 15 N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;

Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸-;

B represents -(C(R¹⁸)₂)_p-Y-(C(R¹⁸)₂)_q-

wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸=CR¹⁸-, p + q = 0-6, and when Y represents a
 20 bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

R¹ R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, -
 25 (C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;

each R⁴ is independently H, F, CF₃ or lower alkyl,
 or two R⁴ groups are taken in conjunction and represent a ring of up to
 30 six atoms, optionally containing one heteroatom selected from O, S(O)_n or N(O)_m;


each R⁵ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, lower alkyl-HET, lower alkenyl-HET or -(C(R¹⁸)₂)_pPh(R¹¹)₀₋₂;

35 each R⁶ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph, Bn and when two R⁶ groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms,

- 5 optionally containing an additional heteroatom selected from O, S(O)_n or N(O)_m;
- each R⁷ is independently H, F, CF₃ or lower alkyl, and when two R⁷ groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing
- 10 from 0-2 heteroatoms selected from O, S(O)_n and N(O)_m;
- each R⁸ represents H or R⁵;
- each R⁹ is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;
- each R¹⁰ is independently lower alkyl, lower alkenyl, lower
- 15 alkynyl, CF₃, Ph(R¹¹)₀₋₃, CH₂Ph(R¹¹)₀₋₃ or N(R⁶)₂;
- each R¹¹ is independently lower alkyl, SR²⁰, OR²⁰, N(R⁶)₂, -CO₂R¹², -CON(R⁶)₂, -C(O)R¹², CN, CF₃, NO₂ or halogen;
- each R¹² is independently H, lower alkyl or benzyl;
- each R¹³ is independently H, halo, lower alkyl, O-lower
- 20 alkenyl, S-lower alkyl, N(R⁶)₂, CO₂R¹², CN, CF₃ or NO₂;
- R¹⁴ and R¹⁵ are independently lower alkyl, halogen, CF₃, OR¹⁶, S(O)_nR¹⁶ or C(R¹⁶)₂OR¹⁷;
- each R¹⁶ is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF₃;
- 25 each R¹⁷ is independently H, lower alkyl or Bn;
- each R¹⁸ is independently H, F or lower alkyl, and when two R¹⁸ groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(O)_n or N;
- 30 each R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl, CF₃, HET(Ra)₄₋₉, lower alkyl-HET(Ra)₄₋₉ or lower alkenyl-HET(Ra)₄₋₉;
- each R²⁰ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃ or Ph(R¹³)₂
- and
- 35 each Ra is independently selected from the group consisting of: H, OH, halo, CN, NO₂, amino, C1-6alkyl, C2-6alkenyl, C2-6alkynyl,

- 5 C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino, di-C₁₋₆alkylamino, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl,
- said alkyl, alkenyl, alkynyl and the alkyl portions of alkylamino and dialkylamino being optionally substituted with 1-3 of:
- 10 hydroxy, halo, aryl, C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆alkyl and N(C₁₋₆alkyl)₂.

- In another embodiment of the invention, the invention
- 15 relates to compounds represented by formula I:



I

as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:

- 20 HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;
- A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-, -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂ or CR⁷=CR⁷, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;
- 25 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;
- Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸-;
- 30 B represents - (C(R¹⁸)₂)_p-Y- (C(R¹⁸)₂)_q-

- 5 wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸ = CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

- 10 R¹, R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, -(C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁶, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;

- each R⁴ is independently H, F, CF₃ or lower alkyl,
15 or two R⁴ groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(O)_n or N(O)_m;

- each R⁵ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, lower alkyl-HET, lower alkenyl-HET or -(C(R¹⁸)₂)_pPh(R¹¹)₀₋₂;
20

- each R⁶ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph, Bn and when two R⁶ groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(O)_n or
25 N(O)_m;

each R⁷ is independently H, F, CF₃ or lower alkyl, and when two R⁷ groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(O)_n and N(O)_m;

- 30 each R⁸ represents H or R⁵;

each R⁹ is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;

each R¹⁰ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph(R¹¹)₀₋₃, CH₂Ph(R¹¹)₀₋₃ or N(R⁶)₂;

- 35 each R¹¹ is independently lower alkyl, SR²⁰, OR²⁰, N(R⁶)₂, -CO₂R¹², -CON(R⁶)₂, -C(O)R¹², CN, CF₃, NO₂ or halogen;

each R¹² is independently H, lower alkyl or benzyl;

- 5 each R^{13} is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, $N(R^6)_2$, CO_2R^{12} , CN, CF_3 or NO_2 ;
 R^{14} and R^{15} are independently lower alkyl, halogen, CF_3 , OR^{16} , $S(O)_nR^{16}$ or $C(R^{16})_2OR^{17}$;
each R^{16} is independently H, lower alkyl, lower alkenyl, Ph,
10 Bn, CHF_2 or CF_3 ;
each R^{17} is independently H, lower alkyl or Bn;
each R^{18} is independently H, F or lower alkyl, and when two R^{18} groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one
15 heteroatom chosen from O, $S(O)_n$ or N;
each R^{19} is lower alkyl, lower alkenyl, lower alkynyl, CF_3 , $HET^2(Ra)_{4-9}$, lower alkyl- $HET^2(Ra)_{4-9}$ or lower alkenyl- $HET^2(Ra)_{4-9}$, wherein HET^2 represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl;
20 each R^{20} is independently H, lower alkyl, lower alkenyl, lower alkynyl, CHF_2 , CF_3 or $Ph(R^{13})_2$
and
each Ra is independently selected from the group consisting of:
25 H, OH, halo, CN, NO_2 , amino, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, C1-6alkylamino, di-C1-6alkylamino, CF_3 , $C(O)C1-6alkyl$, $C(O)C2-6alkenyl$, $C(O)C2-6alkynyl$, CO_2H , $CO_2C1-6alkyl$, $CO_2C2-6alkenyl$, and $CO_2C2-6alkynyl$,
said alkyl, alkenyl, alkynyl and the alkyl portions of
30 alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, C1-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, CF_3 , $C(O)C1-6alkyl$, $C(O)C2-6alkenyl$, $C(O)C2-6alkynyl$, CO_2H , $CO_2C1-6alkyl$, $CO_2C2-6alkenyl$, $CO_2C2-6alkynyl$, NH_2 , $NHC1-6alkyl$ and $N(C1-6alkyl)_2$.
35 An embodiment of the present invention which is of particular interest is represented by formula I wherein HET represents a member selected from the group consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran,

5 thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole.

More particularly, an embodiment of the present invention is represented by formula I wherein HET is selected from the group
10 consisting of: benzene, biphenyl, naphthylene, indole, thiophene, benzofuran and quinoline. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of
15 particular interest is represented by formula I wherein A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO₂, CH₂, -C(O)-, -OCH₂-, -CHOH-, -C(OH)(CH₃)- and -CH₂O-. More particularly, A is selected from the group consisting of: S, S(O), SO₂, CH₂, -C(O)-. Within this subset of compounds of the invention, all
20 other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of particular interest is represented by formula I wherein X represents phenyl optionally substituted with R¹⁴ and R¹⁵. Within this subset of compounds of the invention, all other variables are as originally
25 described with respect to formula I. More particularly, X represents phenyl and R¹⁴ and R¹⁵ are absent or represent halo. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of
30 particular interest is represented by formula I wherein B is CH=CH or 1,2-cyclopropyl, and in particular, where B is CH=CH in the E-isomeric form. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of
35 particular interest is represented by formula I wherein Z is NHSO₂R¹⁹. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

5 Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is $\text{NH}\text{SO}_2\text{R}^{19}$ and R^{19} represents a member selected from the group consisting of: lower alkyl and $\text{HET}(\text{Ra})_3$. Within this aspect of the invention, HET is selected from the group consisting of: phenyl, thienyl, naphthyl,
10 furanyl, thiazolyl, imidazolyl and indolyl.

Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is $\text{NH}\text{SO}_2\text{R}^{19}$ and R^{19} represents benzene or thiophene, substituted with $\text{R}^1\text{R}^2\text{R}^3$.

15 Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z represents OH. Within this subset, all other variables are as originally defined.

A subset of compounds that is of particular interest is defined with respect to formula I wherein:

20 HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole and pyrrole;

25 A represents a one or two atom moiety and is selected from the group consisting of: S, $\text{S}(\text{O})$, SO_2 , CH_2 , $-\text{C}(\text{O})-$, $-\text{OCH}_2-$, $-\text{CHOH}-$, $-\text{C}(\text{OH})(\text{CH}_3)-$ and $-\text{CH}_2-\text{O}-$;

X represents phenyl optionally substituted with R^{14} and R^{15} ;

B is $\text{CH}=\text{CH}$;


30 Z is $\text{NH}\text{SO}_2\text{R}^{19}$ and

R^{19} represents a member selected from the group consisting of: lower alkyl and $\text{HET}(\text{Ra})_3$.

Examples of compounds of the present invention are shown in Tables I and II below.

35

| |
|---------|
| Table I |
|---------|



Ia

(Compounds 1-323 and 347-454)

5

| R¹R²R³-Het | A | X | B | R¹⁹ | Cpd |
|--|-------------------|----------|--------------|-------------------------------------|------------|
| 1-naphthyl | CH ₂ | 1,2-Ph | CH=CH | Ph(F) ₅ | 1 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | Ph(F) ₅ | 2 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 3 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 4 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | phenyl | 5 |
| 3-methylindol -1-yl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 6 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 7 |
| 3,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 8 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 9 |
| 2,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 10 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | Ph(F) ₅ | 11 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 12 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 13 |
| 3,4-chloro fluoro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 14 |
| 1-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 15 |
| 3,4-dichloro phenyl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 16 |
| 4-methylthio phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 17 |
| 4-chlorophenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 18 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 2-thienyl | 19 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 20 |
| 2-naphthyl | S(O) | 1,2-Ph | CH=CH | 2-thienyl | 21 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | phenyl | 22 |
| 2-benzofuranyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 23 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|--------------------------|--------|-------------------------------------|----------------------------------|-----|
| 3,5-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 24 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 25 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 26 |
| 3-(1,2-(methylene dioxy)benzene) | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 27 |
| 2-naphthyl | O | 1,2-Ph | CH=CH | 2-thienyl | 28 |
| Rs-2-phenyl | CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 29 |
| Rs-2-phenyl | CH ₂ | 1,2-Ph | CH ₂ -CH ₂ | 2-thienyl | 30 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 31 |
| 3-((2-(Qn)vinyl)) phenyl | CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 32 |
| 2-(6-benzyloxy) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 33 |
| 3-((2-(Qn)vinyl)) phenyl | SO | 1,2-Ph | CH ₂ -O | 2-thienyl | 34 |
| 3-((2-(Qn)vinyl)) phenyl | -CHOH- | 1,2-Ph | CH ₂ -O | 2-thienyl | 35 |
| 3-((2-(Qn)vinyl)) phenyl | S(O) ₂ | 1,2-Ph | CH ₂ -O | phenyl | 36 |
| 3-((2-(Qn)vinyl)) phenyl | O-CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 37 |
| 3-tolyl-D-3-phenyl | O-CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 38 |
| 3-((2-(Qn)vinyl)) phenyl | CH(OH)-CH ₃ - | 1,2-Ph | CH ₂ -O | phenyl | 39 |
| 3-((2-(Qn)vinyl)) phenyl | S | 1,2-Ph | CH ₂ -O | 2-thienyl | 40 |
| 3-((2-(Qn)vinyl)) phenyl | O | 1,2-Ph | CH ₂ -O | phenyl | 41 |
| 3-((2-(Qn)vinyl)) phenyl | C=O | 1,2-Ph | CH ₂ -O | 2-thienyl | 42 |
| 3-((2-(Qn)vinyl)) phenyl | O | 1,2-Ph | C(CH ₃) ₂ -O | 2-thienyl | 43 |
| 3-((2-(Qn)vinyl)) phenyl | O | 1,2-Ph | CH ₂ -O | 2-thienyl | 44 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 45 |
| 2-(6-benzyloxy) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 46 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichloro phenyl | 47 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluoro phenyl | 48 |

| R¹R²R³-Het | A | X | B | R¹⁹ | Cpd |
|--|-----------------|----------|--------------|---|------------|
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-chloro phenyl | 49 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-propyl phenyl | 50 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro thienyl | 51 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | styryl | 52 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4- fluorophenyl | 53 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxy phenyl | 54 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromo phenyl | 55 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethyl phenyl | 56 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chloro phenyl | 57 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxy phenyl | 58 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluoro phenyl | 59 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-butyl-phenyl | 60 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | butyl | 61 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxy phenyl | 62 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoro methylphenyl | 63 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluoro phenyl | 64 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichloro phenyl | 65 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1- methyl)ethyl) phenyl | 66 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxy methyl)phenyl | 67 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxy methyl)phenyl | 68 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methyl sulfonyl)phenyl | 69 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methyl sulfonyl)phenyl | 70 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propyl sulfonyl)phenyl | 71 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-------------------|--------|--------------|---|-----|
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoro-methyl)-hydroxy methyl)phenyl | 72 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy) phenyl | 73 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1-methyl) ethyl)phenyl | 74 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethyl aminophenyl | 75 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 76 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 77 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinyl | 78 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 79 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 80 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 81 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 82 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)- furanyl | 83 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 84 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro) pyridinyl | 85 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 86 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 87 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 88 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1-methyl)ethyl) phenyl | 89 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxy methyl)phenyl | 90 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxy methyl)phenyl | 91 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethyl phenyl | 92 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxy phenyl | 93 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluoro phenyl | 94 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methyl sulfonyl)phenyl | 95 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methyl sulfonyl)phenyl | 96 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propyl sulfonyl)phenyl | 97 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-------------------|--------|--------------|---|-----|
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-butyl-phenyl | 98 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-di-(CF ₃) phenyl | 99 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoro methyl)-hydroxy methyl)phenyl | 100 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromophenyl | 101 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy) phenyl | 102 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chloro phenyl | 103 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-isopropyl phenyl | 104 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1- methyl) ethyl)phenyl | 105 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxy phenyl | 106 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethyl aminophenyl | 107 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichloro phenyl | 108 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluoro phenyl | 109 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluorophenyl | 110 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 111 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 112 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinyl | 113 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | butyl | 114 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-chlorophenyl | 115 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-propylphenyl | 116 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 117 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 118 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 119 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxy phenyl | 120 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoro methylphenyl | 121 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro-3- thienyl | 122 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 123 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)- furanyl | 124 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 125 |

| R¹R²R³-Het | A | X | B | R¹⁹ | Cpd |
|--|-------------------|----------|--------------|----------------------------------|------------|
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-styryl | 126 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluoro-phenyl | 127 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichloro-phenyl | 128 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro)pyridinyl | 129 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 130 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 131 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 132 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4-fluorophenyl | 133 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-di-(CF ₃)-phenyl | 134 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-isopropylphenyl | 135 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichlorophenyl | 136 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluorophenyl | 137 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluorophenyl | 138 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-chlorophenyl | 139 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-propylphenyl | 140 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro-3-thienyl | 141 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-styryl | 142 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4-fluorophenyl | 143 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxyphenyl | 144 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromophenyl | 145 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethylphenyl | 146 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chlorophenyl | 147 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxyphenyl | 148 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluorophenyl | 149 |

| R¹R²R³-Het | A | X | B | R¹⁹ | Cpd |
|--|-----------------|----------|--------------|--|------------|
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-butylphenyl | 150 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | n-butyl | 151 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxy phenyl | 152 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoro methylphenyl | 153 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluoro phenyl | 154 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichloro phenyl | 155 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1- methyl)ethyl) phenyl | 156 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxy methyl)phenyl | 157 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxy methyl)phenyl | 158 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methyl sulfonyl)phenyl | 159 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methyl sulfonyl)phenyl | 160 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propyl sulfonyl)phenyl | 161 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoro methyl)hydroxy methyl)phenyl | 162 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy) phenyl | 163 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1- methyl) ethyl)phenyl | 164 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethyl aminophenyl | 165 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 166 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 167 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinyl | 168 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 169 |

| R¹R²R³-Het | A | X | B | R¹⁹ | Cpd |
|--|-----------------|----------|--------------|---------------------------------|------------|
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 170 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 171 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 172 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)-furanyl | 173 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 174 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro)pyridinyl | 175 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 176 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 177 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 178 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-di-(CF ₃)phenyl | 179 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-isopropylphenyl | 180 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichlorophenyl | 181 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluorophenyl | 182 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluorophenyl | 183 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-chlorophenyl | 184 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-propylphenyl | 185 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro-3-thienyl | 186 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-styryl | 187 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4-fluorophenyl | 188 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxyphenyl | 189 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromophenyl | 190 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethylphenyl | 191 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|--|-----|
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chloro phenyl | 192 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxy phenyl | 193 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluoro phenyl | 194 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-butylphenyl | 195 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | n-butyl | 196 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxy phenyl | 197 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoromethyl phenyl | 198 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluoro phenyl | 199 |
| 1-(3-methyl)indolyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichloro phenyl | 200 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1-methyl)ethyl) phenyl | 201 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxy methyl)phenyl | 202 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxy methyl)phenyl | 203 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methyl sulfonyl)phenyl | 204 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methyl sulfonyl)phenyl | 205 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propyl sulfonyl)phenyl | 206 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoro methyl)hydroxy methyl)phenyl | 207 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy) phenyl | 208 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1-methyl)ethyl)-phenyl | 209 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethyl aminophenyl | 210 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 211 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|---------------------------------|-----|
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 212 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinyl | 213 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 214 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 215 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 216 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 217 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)-furanyl | 218 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 219 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro)pyridinyl | 220 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 221 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 222 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 223 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃)phenyl | 224 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-isopropylphenyl | 225 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2,3-dichlorophenyl | 226 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,4-difluorophenyl | 227 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-chlorophenyl | 228 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-fluorophenyl | 229 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2,5-dichloro-3-thienyl | 230 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3-chloro-4-fluorophenyl | 231 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-methoxyphenyl | 232 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | butyl | 233 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3-trifluoromethylphenyl | 234 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|-------|-------------------------------------|-----|
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-((1-hydroxy-1-methyl)ethyl)phenyl | 235 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-(methylsulfonyl)phenyl | 236 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-(benzyloxy)phenyl | 237 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | cyclohexyl | 238 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-morpholinyl | 239 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thiazolyl | 240 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-furanyl | 241 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-pyridinyl | 242 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-cyanophenyl | 243 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃)phenyl | 244 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-isopropylphenyl | 245 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2,3-dichlorophenyl | 246 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,4-difluorophenyl | 247 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-chlorophenyl | 248 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-fluorophenyl | 249 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2,5-dichloro-3-thienyl | 250 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3-chloro-4-fluorophenyl | 251 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-methoxyphenyl | 252 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | butyl | 253 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3-trifluoromethylphenyl | 254 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-((1-hydroxy-1-methyl)ethyl)phenyl | 255 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-(methylsulfonyl)phenyl | 256 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-(benzyloxy)phenyl | 257 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | cyclohexyl | 258 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-morpholinyl | 259 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thiazolyl | 260 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-furanyl | 261 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-pyridinyl | 262 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|--------------------|--------|--------------|-------------------------------------|-----|
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-cyanophenyl | 263 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 264 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 265 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 266 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 267 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 268 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 269 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 270 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 271 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 272 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 273 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 274 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 275 |
| 2-(6-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 276 |
| 2-(6-benzyloxy) naphthyl | S | 1,2-Ph | CH=CH | 2-thienyl | 277 |
| 2-(6-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 278 |
| 2-(6-benzyloxy) naphthyl | S | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 279 |
| 2-(5-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 280 |
| 2-(5-benzyloxy) naphthyl | S | 1,2-Ph | CH=CH | 2-thienyl | 281 |
| 2-(5-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 282 |
| 2-(5-benzyloxy) naphthyl | S | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 283 |
| 2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 284 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|----------------------------------|-----|
| 2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 285 |
| 2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 286 |
| 2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 287 |
| 1-(6-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 288 |
| 1-(6-benzyloxy) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 289 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 290 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 291 |
| 2-(6-(4-fluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 292 |
| 2-(7-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 293 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 294 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 295 |
| 2-(6-(4-fluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluoro phenyl | 296 |
| 2-(7-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 297 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 298 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 299 |
| 2-(7-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluoro phenyl | 300 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 301 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁰ | Cpd |
|---|--------------------|-------------|--------------|-------------------------|-----|
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 302 |
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 303 |
| 2-naphthyl | SO | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 304 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 305 |
| 2-naphthyl | O | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 306 |
| 2-(5-benzyloxy)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 307 |
| 2-(5-benzyloxy)naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 308 |
| 2-(5-benzyloxy)naphthyl | S | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 309 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 310 |
| 1,2-Ph | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 311 |
| 2-naphthyl | S | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 312 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 313 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 314 |
| 3-methyl indol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 315 |
| 3-methyl indol-1-yl | S | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 316 |
| 3-methyl indol-1-yl | CH ₂ -O | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 317 |
| 3-methyl indol-1-yl | S | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 318 |
| 3-methyl indol-1-yl | O-CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 319 |
| 3-methyl indol-1-yl | SO | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 320 |
| 3-methyl indol-1-yl | CH ₂ -O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 321 |
| 3-methyl indol-1-yl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 322 |
| 3-methyl indol-1-yl | SO ₂ | 4-Cl-1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 323 |

| R¹R²R³-Het | A | X | B | R¹⁹ | Cpd |
|--|-----------------|---------------------------------|----------|---|------------|
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 347 |
| 2-(7-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 348 |
| 2-(7-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 349 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 350 |
| 2-(7-fluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 351 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 352 |
| 2-(7-fluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 353 |
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 354 |
| 2-(7-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 355 |
| 2-(7-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 356 |
| 2-naphthyl | CH ₂ | 4,5-Cl ₂ - 1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 357 |
| 2-(7-fluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 358 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5- bromophenyl | 359 |
| 2-(7-fluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 360 |
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-trifluoro methoxy-5- chlorophenyl | 361 |
| 2-(7-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-trifluoro methoxy-5- chlorophenyl | 362 |
| 2-(7-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-trifluoro methoxy-5- chlorophenyl | 363 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-trifluoro methoxy-5- chlorophenyl | 364 |
| 2-(7-fluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-trifluoro methoxy-5- chlorophenyl | 365 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-------------|----------|---|-----|
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-trifluoro methoxy-5- chlorophenyl | 366 |
| 2-(7-fluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-trifluoro methoxy-5- chlorophenyl | 367 |
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 368 |
| 2-(7-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 369 |
| 2-(7-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 370 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 371 |
| 2-(7-fluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 372 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 373 |
| 2-(7-fluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 374 |
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 375 |
| 2-(6-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 376 |
| 2-(6-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 377 |
| 2-(6-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 378 |
| 2-(6-fluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 379 |
| 2-(6-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5- bromophenyl | 380 |
| 2-(6-fluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 381 |
| 2-(7-chloro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 382 |
| 2-(7-chloro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 383 |
| 2-(7-chloro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 384 |
| 2-(7-chloro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 385 |
| 2-(7-chloro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 386 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-------------|----------|-----------------------------|-----|
| 2-(7-chloro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 387 |
| 2-(7-chloro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 388 |
| 2-(6,7-difluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 389 |
| 2-(6,7-difluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 390 |
| 2-(6,7-difluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 391 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 392 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 393 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 394 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 395 |
| 2-(6,7-difluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 396 |
| 2-(6,7-difluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 397 |
| 2-(6,7-difluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 398 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 399 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 400 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5- bromophenyl | 401 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 402 |
| 2-(5,7-difluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 403 |
| 2-(5,7-difluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 404 |
| 2-(5,7-difluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 405 |
| 2-(5,7-difluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 406 |
| 2-(6-fluoro) quinolinyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 407 |
| 2-(6-fluoro) quinolinyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 408 |


| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-------------|----------|-------------------------|-----|
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 409 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 410 |
| 2-(6-fluoro)quinolinyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 411 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 412 |
| 2-(5,7-difluoro)-quinolinyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 413 |
| 2-(5,7-difluoro)-quinolinyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 414 |
| 2-(5,7-difluoro)-quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 415 |
| 2-(5,7-difluoro)-quinolinyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 416 |
| 2-(5,7-difluoro)-quinolinyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 417 |
| 2-(5,7-difluoro)-quinolinyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 418 |
| 3,4-dichloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 419 |
| 3,4-dichloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 420 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 421 |
| 3,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 422 |
| 3,4-dichloro phenyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 423 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 424 |
| 3,4-dichloro phenyl | CH ₂ | 5-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 425 |
| 4-chloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 426 |
| 4-chloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 427 |
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 428 |
| 4-chloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 429 |
| 4-chloro phenyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 430 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------------|----------|-------------------------------------|-----|
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 431 |
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 432 |
| 3,4-dichloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 433 |
| 3,4-dichloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 434 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 435 |
| 3,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 436 |
| 3,4-dichloro phenyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 437 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 438 |
| 3,4-dichloro phenyl | CH ₂ | 5-Cl-1,2-Ph | CH=CH | 2-thienyl | 439 |
| 4-chloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 440 |
| 4-chloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 441 |
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 442 |
| 4-chloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 443 |
| 1-(5-chloro) indolyl | CH ₂ | 3,2-Pyr | CH=CH | 2,4-(Me) ₂ -thiazol-5-yl | 444 |
| 1-(5-chloro) indolyl | CH ₂ | 3,2-Pyr | CH=CH | 2-thienyl | 445 |
| 1-(6-(4-chloro) phenyl)indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 3-chloro-4-fluorophenyl | 446 |
| 2-(6-difluoro methoxy) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 447 |
| 2-naphthyl | CH ₂ | 4-MeO-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 448 |
| 2-naphthyl | CH ₂ | 5-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 449 |
| 2-(6-chloro naphthyl) | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 450 |
| 1-(5-phenyl methoxy) indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 451 |

| $R^1R^2R^3$ -Het | A | X | B | R^B | Cpd |
|-------------------------------|--------|------------|---------|-------------------------|-----|
| 2-(benzo[b]thiophenyl) | CH_2 | 4-F-1,2-Ph | $CH=CH$ | 2-methoxy-5-bromophenyl | 452 |
| 5-(1-benzyl)indolyl | CH_2 | 4-F-1,2-Ph | $CH=CH$ | 2-methoxy-5-bromophenyl | 453 |
| 1-(6-(4-chloro)phenyl)indolyl | CH_2 | 4-F-1,2-Ph | $CH=CH$ | 2-methoxy-5-bromophenyl | 454 |

5

Table II



I-b

(Compounds 324-346 and 455-542)

| $R^1R^2R^3$ -Het | A | X | B | Cpd |
|-------------------------|----------|------------|--------------|-----|
| 2-naphthyl | $S(O)_2$ | 1,2-phenyl | $CH=CH$ | 324 |
| 2-naphthyl | S | 1,2-phenyl | $CH=CH$ | 325 |
| 4-methylthiophenyl | CH_2 | 1,2-phenyl | $CH=CH$ | 326 |
| 3-methylindol-1-yl | CH_2 | 1,2-phenyl | $CH=CH$ | 327 |
| 3-chloro-4-fluorophenyl | CH_2 | 1,2-phenyl | $CH=CH$ | 328 |
| 4-chlorophenyl | CH_2 | 1,2-phenyl | $CH=CH$ | 329 |
| 2-naphthyl | CH_2 | 1,2-phenyl | $CH=CH$ | 330 |
| 2-naphthyl | $S(O)_2$ | 1,2-phenyl | 1,2-c-propyl | 331 |
| 2-naphthyl | $S(O)_2$ | 1,2-phenyl | CH_2-CH_2 | 332 |
| 2-naphthyl | S | 1,2-phenyl | $CH=CH$ | 333 |
| 3,4-dichlorophenyl | $S(O)_2$ | 1,2-phenyl | CH_2-CH_2 | 334 |
| 3,4-dichlorophenyl | CH_2 | 1,2-phenyl | $CH=CH$ | 335 |
| 2-(6-benzyloxy)naphthyl | CH_2 | 1,2-phenyl | $CH=CH$ | 336 |
| 2-(6-benzyloxy)naphthyl | CH_2 | 1,2-phenyl | 1,2-c-propyl | 337 |
| 2-(6-benzyloxy)naphthyl | SO_2 | 1,2-phenyl | 1,2-c-propyl | 338 |
| 2-(6-benzyloxy)naphthyl | CH_2-O | 1,2-phenyl | 1,2-c-propyl | 339 |
| 2-(6-benzyloxy)naphthyl | $O-CH_2$ | 1,2-phenyl | 1,2-c-propyl | 340 |
| 2-(6-benzyloxy)naphthyl | SO_2 | 1,2-phenyl | $CH=CH$ | 341 |
| 2-(6-benzyloxy)naphthyl | CH_2-O | 1,2-phenyl | $CH=CH$ | 342 |

| R ¹ R ² R ³ -Het | A | X | B | Cpd |
|---|-------------------|-------------|----------|-----|
| 2-(6-benzyloxy)naphthyl | O-CH ₂ | 1,2-phenyl | CH=CH | 343 |
| 2-(6-benzyloxy)naphthyl | S | 1,2-phenyl | CH=CH | 344 |
| 2-(7-benzyloxy)naphthyl | SO ₂ | 1,2-phenyl | CH=CH | 345 |
| 2-(6-(4-trifluoromethyl)benzyloxy)naphthyl | CH ₂ | 1,2-phenyl | CH=CH | 346 |
| 2-(6-fluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 455 |
| 2-(6-fluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 456 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 457 |
| 2-(6-fluoro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 458 |
| 2-(6-fluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 459 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 460 |
| 2-(7-fluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 461 |
| 2-(7-fluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 462 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 463 |
| 2-(7-fluoro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 464 |
| 2-(7-fluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 465 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 466 |
| 2-(6-chloro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 467 |
| 2-(6-chloro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 468 |
| 2-(6-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 469 |
| 2-(6-chloro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 470 |
| 2-(6-chloro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 471 |
| 2-(6-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 472 |
| 2-(7-chloro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 473 |
| 2-(7-chloro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 474 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 475 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 476 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 477 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 478 |
| 2-(6,7-difluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 479 |
| 2-(6,7-difluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 480 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 481 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 482 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 483 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 484 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 485 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 486 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 487 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 488 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 489 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 490 |
| 3-methyl-5-fluoro indol-1-yl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 491 |

| R ¹ R ² R ³ -Het | A | X | B | Cpd |
|---|-----------------|-------------|-------|-----|
| 3-methyl-5-fluoro indol-1-yl | S | 4-Cl-1,2-Ph | CH=CH | 492 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 493 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 1,2-Ph | CH=CH | 494 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 495 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 496 |
| 2-(6-fluoro)quinolinyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 497 |
| 2-(6-fluoro)quinolinyl | S | 4-Cl-1,2-Ph | CH=CH | 498 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 499 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 500 |
| 2-(6-fluoro)quinolinyl | O | 4-Cl-1,2-Ph | CH=CH | 501 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 502 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 503 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 504 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 505 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 506 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 507 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 508 |
| 2-(7-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 509 |
| 2-(7-difluoromethoxy)- naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 510 |
| 2-(7-difluoromethoxy)- naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 511 |
| 2-(7-difluoromethoxy)- naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 512 |
| 2-(7-difluoromethoxy)- aphthyl | O | 4-Cl-1,2-Ph | CH=CH | 513 |
| 2-(7-difluoromethoxy)- naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 514 |
| 2-(6-methoxy)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 515 |
| 2-(6-methoxy)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 516 |
| 2-(6-methoxy)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 517 |
| 2-(6-methoxy)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 518 |

| R ¹ R ² R ³ -Het | A | X | B | Cpd |
|---|-----------------|-----------------------------|-------|-----|
| 2-(6-methoxy)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 519 |
| 2-(6-methoxy)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 520 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 521 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 522 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 523 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 524 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 525 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 526 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 527 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 528 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 529 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 530 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 531 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 532 |
| 2-naphthyl | CH ₂ | 4,5-Cl ₂ -1,2-Ph | CH=CH | 533 |
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 534 |
| 3,4-dichlorophenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 535 |
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 536 |
| 4-chlorophenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 537 |
| 1-(5-phenylmethoxy) indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 538 |
| 2-(benzo[b]thiophenyl) | CH ₂ | 4-F-1,2-Ph | CH=CH | 539 |
| 5-(1-benzyl)indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 540 |
| 1-(6-(4-chloro)phenyl) indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 541 |
| 1-(5-chloro)indolyl | CH ₂ | 3,2-Pyr | CH=CH | 542 |

5

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.

10

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

15

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a

5 pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from
10 ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted
15 amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine,
20 glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts
25 may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric,
30 pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that in the discussion of methods of
35 treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

The magnitude of prophylactic or therapeutic dose of a compound of Formula I will, of course, vary with the nature and the

5 severity of the condition to be treated and with the particular compound
of Formula I and its route of administration. It will also vary according
to a variety of factors including the age, weight, general health, sex, diet,
time of administration, rate of excretion, drug combination and
response of the individual patient. In general, the daily dose from about
10 0.001 mg to about 100 mg per kg body weight of a mammal, preferably
0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to
use dosages outside these limits in some cases.

The amount of active ingredient that may be combined with
the carrier materials to produce a single dosage form will vary
15 depending upon the host treated and the particular mode of
administration. For example, a formulation intended for oral
administration to humans may contain from about 0.5 mg to about 5 g of
active agent compounded with an appropriate and convenient amount of
carrier material which may vary from about 5 to about 95 percent of the
20 total composition. Dosage unit forms will generally contain from about 1
mg to about 2 g of an active ingredient, typically 25 mg, 50 mg, 100 mg,
200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

For the treatment of any of the prostanoid mediated diseases
compound I may be administered orally, topically, parenterally, by
25 inhalation spray or rectally in dosage unit formulations containing
conventional non-toxic pharmaceutically acceptable carriers, adjuvants
and vehicles. The term parenteral as used herein includes
subcutaneous, intravenous, intramuscular, intrasternal injection or
infusion techniques. In addition to the treatment of warm-blooded
30 animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the
compound of the invention is effective in the treatment of humans.

The pharmaceutical compositions containing the active
ingredient may be in a form suitable for oral use, for example, as tablets,
troches, lozenges, solutions, aqueous or oily suspensions, dispersible
35 powders or granules, emulsions, hard or soft capsules, syrups or
elixirs. Compositions intended for oral use may be prepared according
to any method known to the art for the manufacture of pharmaceutical
compositions and such compositions may contain one or more agents

- 5 selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- 10 These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate,
- 15 stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be
- 20 coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or

25 kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in

30 admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-

35 occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or

5 condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more
10 preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil,
15 sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an
20 anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting
25 agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a
30 vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation
35 products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

5 Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous
10 suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a
15 solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this
20 purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

 Compound I may also be administered in the form of suppositories for rectal administration of the drug. These compositions
25 can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

 For topical use, creams, ointments, gels, solutions or
30 suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

35 The ability of the compounds of Formula I to interact with prostaglandin receptors makes them useful for treating, preventing or reversing undesirable symptoms caused by prostaglandins in a mammalian, especially human subject. This mimicking or antagonism

5 of the actions of prostaglandins indicates that the compounds and
pharmaceutical compositions thereof are useful to treat, prevent or
ameliorate prostaglandin mediated diseases and conditions in
mammals and especially in humans: Pain, fever and inflammation of a
variety of conditions including rheumatic fever, symptoms associated
10 with influenza or other viral infections, common cold, low back and neck
pain, skeletal pain, post-partum pain, dysmenorrhea, headache,
migraine, toothache, sprains and strains, myositis, neuralgia,
synovitis, arthritis, including rheumatoid arthritis, degenerative joint
diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis,
15 burns including radiation and corrosive chemical injuries, sunburns,
pain following surgical and dental procedures as well as immune and
autoimmune diseases. In addition, such a compound may inhibit
cellular neoplastic transformations and metastatic tumor growth and
hence can be used in the treatment of cancer. Compound I may also be
20 of use in the treatment and/or prevention prostaglandin-mediated
proliferation disorders such as may occur in diabetic retinopathy and
tumor angiogenesis. Compound I will also inhibit prostanoid-induced
smooth muscle contraction by antagonizing contractile prostanoids or
mimicking relaxing prostanoids and hence may be use in the treatment
25 of dysmenorrhea, premature labor, asthma and eosinophil related
disorders. It will also be of use in the treatment of Alzheimer's disease,
the treatment of glaucoma, for the prevention of bone loss (treatment of
osteoporosis) and for the promotion of bone formation (treatment of
fractures) and other bone diseases such as Paget's disease.

30 By virtue of its prostanoid or prostanoid antagonist activity,
compound I will prove useful as an alternative to NSAID'S particularly
where such non-steroidal anti-inflammatory drugs may be
contraindicated such as in patients with peptic ulcers, gastritis,
regional enteritis, ulcerative colitis, diverticulitis or with a recurrent
35 history of gastrointestinal lesions; GI bleeding, coagulation disorders
including anemia such as hypoprothrombinemia, haemophilia or other
bleeding problems; kidney disease; thrombosis, occlusive vascular
diseases; those prior to surgery or taking anti-coagulants. Compound I

- 5 will also be useful as a cytoprotective agent for patients under chemotherapy.

Compound of Formula I, will be useful as a partial or complete substitute for conventional antiinflammatory or analgesic compounds in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating prostaglandin E_2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a COX-2 selective NSAID; a conventional NSAID; a potentiator including caffeine; an H_2 -antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; another prostaglandin ligand including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition, the invention encompasses a method of treating prostaglandin E_2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

- 30 Compounds of the present invention can be prepared according to the following methods. Temperatures are in degrees Celsius.

Boronic acids and esters can be prepared from the corresponding halide according to literature procedure and reference cited therein (Charette, A.B.; Giroux, A. J. Org. Chem. 1996, 61, 8718; Ishiyama, T.; Murata, M.; Miyaura, N. J. Org. Chem. 1995, 60, 7508; Miyaura, N.; Suzuki, A. Chem. Rev, 1995, 95, 2457; Murata, M.; Watanabe, S.; Masuda, Y. J. Org. Chem. 1997, 62, 6458; Watanabe, T.

- 5 Miyaura, N.; Suzuki, A. Synlett, 1992, 207; Maddaford, S.; Keay, B.A. J. Org. Chem. 1994, 59, 6501; Cristofoli, W.A.; Keay, B.A. Tetrahedron Lett. 1991, 32, 5881; Passafaro, M.S.; Keay, B.A. . Tetrahedron Lett. 1996, 37, 429; Serafin, B.; Makosza, M. Tetrahedron, 1963, 19, 821). In some cases, the triflate, the tin or the zinc derivatives may be used instead of the
10 boronic acid.

Method A

- Cinnamic ester **1** is treated with a brominating agent such as NBS in a refluxing inert solvent such as CCl_4 , with the use of an
15 initiator like benzoyl peroxide or light. The resulting benzylic bromide is reacted in a Suzuki coupling reaction with the appropriate boronic acid or ester, a catalyst such as tetrakis(triphenylphosphine) palladium and cesium fluoride or Na_2CO_3 or a base in an inert refluxing solvent such as DME at $80-90^\circ\text{C}$. The new cinnamic ester **3** is hydrolyzed with aqueous
20 sodium hydroxide to afford the acid **4** that is converted to the cinnamic sulfonamide **5** with a coupling reagent such as DCC or DCI in CH_2Cl_2 at r.t.

5 Method B

Cinnamic ester **2** is treated with an aryl or heteroaryl mercaptan, alcohol or amine, and with a base such as a hydride or an amine in benzene or THF at 0-23° C. The resulting cinnamic ester **6** is converted to **7** according to Method A.

- 10 If W= sulfur, it is oxidized to the sulfoxide or sulfone **8** with hydrogen peroxide, m-CPBA or other peracetic acid. The cinnamic ester **8** is converted to **9** according to Method A.

Method C

- 15 The aldehyde **11** is prepared by an addition-elimination of a mercapto, hydroxy or amino aryl or heteroaryl with a base such as K_2CO_3 in refluxing $CHCl_3$. If needed a higher boiling point solvent can be used. This type of reaction can also be performed with CuO in DMF. An Emmons-Horner type reaction (or Wittig) in toluene at r.t. followed
20 by Method A (or oxidation as described in Method B) results in the cinnamic sulfonamide **13**.

Method D

- Acetal **14** that came from an acetalization from a suitably
25 substituted bromo benzaldehyde is converted to the Grignard reagent with magnesium in an etheral solvent at reflux and quenched with an aryl or heteroaryl ketone. The alcohol **16** is reacted with an halide and a base (or protected as the *o*-nitrobenzyl, and removed at the end of the sequence) to furnish the compound **17**. Deprotection of the acetal under
30 standard conditions followed by Method C gives **18**.

Method E

- Alcohol **16** is converted to an acetate with acetyl chloride (or acetic anhydride and an amine base) and coupled with a Grignard
35 reagent and a copper salt at low temperature. The alcohol **16** could also be converted to the bromide and treated in a similar way to yield **20**. Alternatively the tetramethyl acetal (R= methyl) version of alcohol **16** can be treated with $TiCl_4/Me_2Zn$ (or R^7_2Zn) at -30 °C. Compound **20** is then

5 converted to the cinnamic sulfonamide **21** according to Method D. Also, **22** can be treated with $\text{Al}(\text{R}^7)_3$ in toluene at 80 °C for 24h and **23** converted to the aldehyde with n-BuLi/DMF followed by an Emmons-Horner reaction and Method A to yield compound **21**.

10 Method F

A suitably substituted bromo toluene **24** is treated with n-Buli at low temperature and quenched with an aryl or heteroaryl aldehyde. The resulting alcohol is oxidized to the ketone with PDC, PCC, MnO_2 or other typical oxidizing agent. The carbonyl is treated with SF_4 ,
15 $\text{MoF}_6\text{-BF}_3$ (or converted to a thioacetal and treated with nitrosonium $\text{BF}_4\text{-pyridinium}\cdot\text{HF}$) to yield the difluoride. Benzylic bromination with NBS followed by oxidation with N-methylmorpholine N-oxide at 100 °C in dioxane for 4 h, yielded compound **25** that is converted to cinnamic sulfonamide **26** with Method C.

20

Method G

The appropriately substituted methyl bromo(or triflate) benzoate **27** is converted to compound **28** by a Suzuki coupling reaction followed by hydrogenation. A Stille coupling reaction could also be used.
25 Benzylic bromination or benzylic oxidation followed by treatment with a brominating agent such as CBr_4 /triphenylphosphine gives compound **29** which can be treated with a boronic acid, or a tin compound (Stille) to furnish compound **30**. Reduction of the ester with DIBAL, oxidation with MnO_2 and Method C gives compound **31**.

30

Method H

Compound **29** (one $\text{R}^7 = \text{H}$) is treated with triphenyl phosphine to give the salt and, with a base such as LDA, is converted to compound **32** with the aryl or heteroaryl ketone. The halide **29** can also
35 be converted the Grignard reagent and added to the ketone. Dehydration under acidic conditions results in compound **32**. Reduction of the double bond under standard conditions, followed by Methods G and C gives compound **33**. From compound **32**, cyclopropanation with

- 5 diazomethane and palladium (0) followed by Methods G, C and A gives compound **34**.

5 Method I

The (heterocyclic) vinylic bromide **35** is reacted in a Suzuki coupling reaction with an aryl or hetero aryl boronic acid and converted to a new borane by 9-BBN addition followed by a second Suzuki reaction with compound **14**. Compound **37** thus formed is reduced by
10 hydrogenolysis (H_2 /metal or diimide) and deprotection followed by Method C gives cinnamic sulfonamide **39**.

Method J

Ketone **40** which comes from oxidation of the corresponding
15 alcohol is reacted with a phosphonium salt or phosphono ester with a base such as LDA to give the cinnamic ester **41**. Method A yields **42** and reduction of the double bond by the previously mentioned method gives the acyl sulfonamide **43**.

20 Method K

Cinnamic ester **3** is reduced to **44** by the previously mentioned method. α Alkylation with a base such as LDA followed by an alkylating agent results in **45** after conversion to the acyl sulfonamide.

25 Method L

Cinnamic ester **3** is reduced to **46** with DIBAL and the double bond converted to a cyclopropane by a Simmons-Smith reaction, or similar reactions recently described in the literature. Compound **47** is then oxidized and the cinnamic sulfonamide **48** is prepared according to
30 Method A.

Method M

Ester **49** which can come from the homologation of the appropriately substituted methyl ortho-toluate, is treated with a base and
35 with an alkylating agent to furnish compound **50**. Benzylic bromination and Suzuki coupling gives an intermediate ester. Homologation according to *J. Amer. Chem. Soc.*; **1985**, 1429; *J. Org. Chem.* **1992**, 7194,

- 5 followed by alkylation with a base such as LDA and an alkylating agent furnishes acylsulfonamide **51** by Method A.

Compound **50** can also be converted to the benzylic bromide and to compound **52** by Method A.

10 Method N

Suitably substituted compound **53** is treated with a boronic acid to give compound **54** which is reduced with LDA to the alcohol **55**. Treatment with phosgene followed with the appropriate sulfonamide gives compound **56**. This can also be prepared by mixing phosgene and
15 the sulfonamide at 140°C to generate the isocyanate.

Compound **54** is treated with a Grignard reagent to give the corresponding alcohol and as previously described, converted to compound **57**.

20 Method O

Ester **58** is treated with Lawesson's reagent, DAST and light to give the benzylic alcohol **59**. The procedure according to Method N yields compound **60**.

25 Method P

Compound **59** is brominated as described earlier (or iodinated) and reacted in a S_N2 type reaction with an ester and a base such as LDA to furnish ester **61**. Method A gives the acylsulfonamide
30 **62**.

30

Method Q

Compound **55** is treated with $NH_3/Ph_3P/DEAD$ (or treated with CBr_4/Ph_3P and the bromide converted to the amine **63** with ammonia). Treatment with phosgene followed by sulfonamide yields **64**,
35 treatment of which with a base and an alkyl or benzylic halide gives compounds **65**.

Method R

5 Aldehyde **10** is treated with a silylated source of hydroxyl or
thiol at 80-130 °C, and the silyl group removed by fluoride treatment.
Compound **66** is then treated with an aryl or heteroaryl methylene
bromide with a base such as a tertiary amine in CHCl_3 or benzene to
yield aldehyde **67**. Emmons-Horner (or Wittig reaction) with LDA
10 results in compound **68** via Method A.

Method S


 In the case of an amine an alternative to method R can be
used. A suitably substituted nitro aldehyde **69** is converted to compound
15 **70** as described earlier and the nitro group reduced with standard
methods. Mono-alkylation followed by displacement with an aryl or
heteroaryl methylene bromide and processing by Method A yields
cinnamic sulfonamide **71**.

20 Method T


 A suitably substituted bromo toluene **24** is converted to the
anion in an etheral solvent at low temperature and trapped with an
aldehyde of an aryl or heteroaryl. The resulting alcohol is oxidized with
 MnO_2 , Jones' reagent, PDC, PCC or any other oxidant. Benzylic
25 bromination followed by oxidation with N-methyl morpholine N-oxide,
yields a ketoaldehyde. Emmons-Horner and Method A gives the
cinnamic sulfonamides **72**.

 Generic structures 4, 5, 7, 9, 13, 18, 21, 26, 31, 33, 34, 39, 42,
30 43, 45, 48, 51, 52, 56, 57, 60, 62, 64, 65, 68, 71 and 72 are representative of
the compounds of the present invention. It is also noted that where the
chemistry allows in the generic schemes, alternate embodiments of -A-,
such as heteroaryl groups, can be substituted for phenyl in the schemes.

Method A




Method B




5


Method C



Method D




R= H, Methyl




5


Method E




Method F



Method G




Method H





5


Method I





Method J





5




Method K




Method L





Method M



Method N




Method O






5


Method P



Method Q




Method R




5

Method S



5



ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY

Biological activity and thus utility for the compounds of formula I as modulators of prostaglandin mediated diseases can be demonstrated in accordance with the following assays which demonstrate prostanoid antagonist or agonist activity *in vitro* and *in vivo* and their selectivity. The prostaglandin receptors investigated were DP, EP₁, EP₂, EP₃, EP₄, FP, IP and TP.

Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293(ebna) cell line

5 Prostanoid receptor cDNAs corresponding to full length
coding sequences were subcloned into the appropriate sites of
mammalian expression vectors and transfected into HEK 293(ebna)
cells. HEK 293(ebna) cells expressing the individual cDNAs were grown
under selection and individual colonies were isolated after 2-3 weeks of
10 growth using the cloning ring method and subsequently expanded into
clonal cell lines.

Prostanoid receptor binding assays

HEK 293(ebna) cells are maintained in culture, harvested
15 and membranes are prepared by differential centrifugation, following
lysis of the cells in the presence of protease inhibitors, for use in receptor
binding assays. Prostanoid receptor binding assays are performed in 10
mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4)
(DP and IP), containing 1 mM EDTA, 10 mM divalent cation and the
20 appropriate radioligand. The reaction is initiated by addition of
membrane protein. Ligands are added in dimethylsulfoxide which is
kept constant at 1 % (v/v) in all incubations. Non-specific binding is
determined in the presence of 1 μ M of the corresponding non-radioactive
prostanoid. Incubations are conducted for 60 min at room temperature
25 or 30 °C and terminated by rapid filtration. Specific binding is calculated
by subtracting non specific binding from total binding. The residual
specific binding at each ligand concentration is calculated and
expressed as a function of ligand concentration in order to construct
sigmoidal concentration-response curves for determination of ligand
30 affinity.

Prostanoid receptor agonist and antagonist assays

Whole cell second messenger assays measuring
stimulation (EP₂, EP₄, DP and IP in HEK 293(ebna) cells) or inhibition
35 (EP₃ in human erythroleukemia (HEL) cells) of intracellular cAMP
accumulation or mobilization of intracellular calcium (EP₁, FP and TP
in HEK 293(ebna) cells stably transfected with apo-aequorin) are
performed to determine whether receptor ligands are agonists or

- 5 antagonists. For cAMP assays, cells are harvested and resuspended in HBSS containing 25 mM HEPES, pH 7.4. Incubations contain 100 μ M RO-20174 (phosphodiesterase type IV inhibitor, available from Biomol) and, in the case of the EP₃ inhibition assay only, 15 μ M forskolin to stimulate cAMP production. Samples are incubated at 37°C for 10 min,
- 10 the reaction is terminated and cAMP levels are then measured. For calcium mobilization assays, cells are charged with the co-factors reduced glutathione and coelenterazine, harvested and resuspended in Ham's F12 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular
- 15 photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. For agonists, second messenger responses are expressed as a function of ligand concentration and both EC₅₀ values and the maximum response as compared to a prostanoid standard are calculated. For antagonists, the
- 20 ability of a ligand to inhibit an agonist response is determined by Schild analysis and both K_b and slope values are calculated.

Rat Paw Edema Assay

- The method is the same as described in Chan *et al* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).
- 25

LPS-Induced Pyrexia in Conscious Rats

- The method is the same as described in Chan *et al* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).
- 30

LPS-Induced Pyrexia in Conscious Squirrel Monkeys

- The method is the same as described in Chan *et al* (Eur. J. Pharmacol. 327: 221- 225, 1997).
- 35

Acute Inflammatory Hyperalgesia Induced by Carrageenan in Rats

- The method is the same as described in Boyce *et al* (Neuropharmacology 33: 1609-1611, 1994).

5 Adjuvant-Induced Arthritis in Rats

Female Lewis rats (body weight ~146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of *Mycobacterium butyricum* in 0.1 mL of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 mL of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds were

- 5 prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.

The invention is illustrated in connection with the following non-limiting Examples. All the end products of the formula I were analyzed by NMR, TLC and mass spectrometry.

- 10 Intermediates were analyzed by NMR and TLC.

Most compounds were purified by flash chromatography on silica gel. Recrystallization and/or swish (suspension in a solvent followed by filtration of the solid) with a solvent such as ether:hexane 1:1.

- 15 The course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only.

Temperatures are in degrees Celsius.

The compounds of the examples are numbered in accordance with the compounds that appear in Tables I and II.

20

EXAMPLE 1

N-((E)-3-{2-[4-(METHYLTHIO)BENZYL]PHENYL}-2-PROPENOYL)-2-
THIOPHENESULFONAMIDE (17)

- 25 Step 1: Methyl (E)-3-(2-methylphenyl)-2-propenoate

- To 2-methylcinnamic acid (100g; 617 mmol) in 1.2 L of DMF was added DBU (112.6 g; 740 mmol) and 15 min later methyl iodide (131.3 g; 925 mmol) and left overnight. The solution was diluted in ether and washed with HCl (10%), H₂O and brine. The solvent was removed to
30 give 106.8 g of the title compound.

¹H NMR (CDCl₃) δ 2.4 (3H, s), 3.8 (3H, s), 6.35 (1H, d), 7.15 (1H, t), 7.22 (1H, t), 7.5 (1H, d) and 7.95 (1H, d).

- The ethyl ester can be prepared as well in the same way or from the 2-methyl benzaldehyde (5.00 g; 41.6 mmol) and triethyl
35 phosphonoacetate (9.9 mL; 50.0 mmol) in 150 mL of toluene at 0 °C, to which was added portionwise NaH (63.0 mmol). After 2 h of stirring the mixture was quenched with NH₄OAc (25%) and extracted with EtOAc. The solvent was removed to give 7.1 g of the ethyl cinnamate.

5 Step 2: Ethyl (E)-3-[2-(bromomethyl)phenyl]-2-propenoate

To the previous ethyl cinnamate (20.0 g; 105 mmol) and NBS (19.64 g; 110.3 mmol) in refluxing CCl_4 was added benzoyl peroxide (1.27 g) and the mixture was stirred for 12 h. The solution was cooled to r.t. and filtered. The solvent was removed and the crude oil purified by
10 silica gel chromatography (5% EtOAc in hexane) to yield 14.18 g of the title compound.

^1H NMR (CDCl_3) δ 1.30 (3H, t), 4.25 (2H, q), 4.60 (2H, s), 6.45 (1H, d), 7.30 (3H, m), 7.57 (1H, m) and 8.05 (1H, d).

5 Step 3: Ethyl (E)-3-[2-[4-(methylthio)benzyl]phenyl]-2-propenoate

A mixture of the previous benzyl bromide (0.50 g; 1.86 mmol), 4-(methylthio)benzeneboronic acid (0.63 g; 3.7 mmol) CsF (1.13 g) and (Ph₃P)₄Pd (0.11 g) in 10 mL of DME was heated to reflux for 10 h. The mixture was cooled to r.t. and quenched with NH₄OAc (25%) and
10 extracted with EtOAc. The organic phases were combined, dried and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 0.35 g of the title compound.

¹H NMR (CDCl₃) δ 1.27 (3H, t), 2.41 (3H, s), 4.08 (2H, s), 4.21 (2H, q), 6.30 (1H, d), 7.00 (1H, d), 7.1-7.4 (6H, m), 7.55 (1H, d) and 7.97 (1H,
15 d).

Step 4: (E)-3-[2-[4-Methylthio)benzyl]phenyl]-2-propenoic acid

Hydrolysis of the previous ester (0.34 g; 1.1 mmol) was run in THF/MeOH (6 mL/3 mL) with 2 equivalent of a 2N NaOH solution for 4
20 h. The solution was diluted with EtOAc and quenched with HCl (10%). The organic phase was dried over Na₂SO₄ and the solvent removed. Purification was done by a swish in hexane to yield 0.21 g of the title compound.

¹H NMR (CDCl₃) δ 2.42 (3H, s), 4.09 (2H, s), 6.31 (1H, d), 7.00-
25 7.35 (7H, m), 7.50 (1H, d) and 8.07 (1H, d).

Step 5: N-((E)-3-[2-[4-(methylthio)benzyl]phenyl]-2-propenoyl)-2-thiophenesulfonamide (17)

2-Thiophenesulfonamide was prepared from the
30 corresponding sulfonyl chloride with 2.2 equivalent of NH₄OH in THF at 0 °C. The solution was brought to r.t. and left 2 h. It was then quenched with NaHCO₃ and extracted with EtOAc. The organic phase was dried over Na₂SO₄ and the solvent removed. The crude product was crystallized in toluene/EtOAc.

35 To the previous acid (100 mg; 0.35 mmol), 2-thiophenesulfonamide (60 mg; 0.37 mmol), DMAP (86 mg; 0.7 mmol) in 2 mL of CH₂Cl₂ was added DCI (134 mg; 0.7 mmol) and the mixture was stirred overnight. The solution was diluted with EtOAc and quenched

5 with HCl (10%). The organic phase was dried over Na_2SO_4 and the solvent removed. Purification by silica gel chromatography (5% MeOH in CH_2Cl_2) yielded 87 mg of the title compound.

^1H NMR (CDCl_3) δ 2.40 (3H, s), 4.01 (2H, s), 6.33 (1H, d), 6.9-7.3 (8H, m), 7.49 (1H, d), 7.61 (1H, s), 7.89 (1H, s) and 8.03 (1H, d). The
10 product was converted to the sodium salt with 1 equivalent of NaOH and freeze dried.

Elemental analysis calcd. for $\text{C}_{21}\text{H}_{18}\text{NNaO}_3\text{S}_3 \cdot 1/2\text{H}_2\text{O}$: C, 54.77; H, 4.13; N, 3.04; S, 20.88; Found: C, 54.55; H, 4.01; N, 3.06; S, 20.58.

15 **EXAMPLE 2**

N-((E)-3-{2-[(3-methyl-1H-1-indolyl)methyl]phenyl}-2-propenoyl)-2-thiophenesulfonamide (3)

20 **Step 1: Ethyl (E)-3-{2-[(3-methyl-1H-1-indolyl)methyl]phenyl}-2-propenoate**

To benzylic bromide (400 mg, 1.49 mmol) of step 2 in example 1 and skatole (200mg, 1.51 mmol) in 6 mL of DMF was added portionwise 1.6 equivalent of NaH. The reaction mixture was left for 6 h and quenched with NH_4OAc (25%) and diluted with EtOAc. The organic
25 phase was dried over Na_2SO_4 , filtered and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 260mg of the title compound.

^1H NMR (CDCl_3) δ 1.2 (3H, t), 2.3 (3H, s), 4.25 (2H, q), 5.4 (2H, s), 6.35 (1H, d), 6.65 (1H, d), 6.8 (1H, s), 7.1-7.3 (5H, m), 7.56 (2H, d) and
30 7.97 (1H, d).

Step 2: (E)-3-{2-[(3-methyl-1H-1-indolyl)methyl]phenyl}-2-propenoic acid

The hydrolysis of the previous ester (260 mg) was done according to Step 4 of example 1 to yield 212 mg of the title compound.

35 HRMS calcd. for $\text{C}_{19}\text{H}_{17}\text{NO}_3 + \text{H}^+ = 292.1337$; Found: 292.1337.

Step 3: N2-((E)-3-{2-[(3-methyl-1H-1-indolyl)methyl]phenyl}-2-propenoyl)-2-thiophenesulfonamide (3)

5 The coupling reaction of the previous acid (196 mg; 0.67 mmol) was done according to step 5 of example 1 to yield 134 mg of the title compound.

¹H NMR (acetone-d₆) δ 2.39 (3H, s), 5.57 (2H, s), 6.65 (2H, m), 7.03 (3H, m), 7.27 (4H, m), 7.5 (1H, d), 7.63 (1H, d), 7.87 (1H, d), 7.95 (1H, s) and 8.14 (1H, d).

 HRMS calcd. for C₂₃H₂₀N₂O₃S₂ + H⁺ = 437.0994; Found: 437.0992.

EXAMPLE 3

15 N-[(E)-3-[2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL]-2-
 THIOPHENESULFONAMIDE (4)

Step 1: Ethyl (E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoate

 The benzyl bromide (500 mg) of example 1, step 2 was
20 treated with 2-naphthylboronic acid according to the same procedure previously described to yield 360 mg of the title compound.

¹H NMR (CDCl₃) δ 1.30 (3H, t), 4.27 (2H, q), 4.33 (2H, s), 6.48 (1H, d), 7.2-7.4 (4H, m), 7.45 (2H, m), 7.55 (1H, s), 7.62 (1H, d), 7.8 (3H, m) and 8.15 (1H, d).

Step 2: (E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoic acid

 The hydrolysis of the previous ester (300 mg) was done according to Step 4 of example 1 to yield 202 mg of the title compound.

¹H NMR (CDCl₃) δ 4.29 (2H, s), 6.32 (1H, d), 7.2-7.4 (6H, m),
30 7.5 (1H, s), 7.62 (1H, d), 7.73 (3H, m) and 8.19 (1H, d).

Step3: N-[(E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (4)

 The coupling reaction of the previous acid (100 mg; 0.35
35 mmol) was done according to step 5 of example 1 to yield 60 mg of the title compound.

¹H NMR (CDCl₃) δ 4.24 (2H, s), 6.31 (1H, d), 7.02 (1H, m), 7.15-7.8 (12H, m), 7.84 (1H, m) and 8.08 (1H, d).

5 The acid was converted to the sodium salt with 1 equivalent of NaOH.

Elemental analysis calcd. for $C_{24}H_{18}NNaO_3S_2 \cdot H_2O$: C, 60.87; H, 4.22; N, 2.96; S, 13.54; Found: C, 60.36; H, 4.25; N, 3.29; S, 12.53.

5

EXAMPLE 4

N-[(E)-3-[2-(3,4-DICHLOROBENZYL)PHENYL]-2-PROPENOYL]-2-
THIOPHENESULFONAMIDE (8)Step 1: Ethyl (E)-3-[2-(3,4-dichlorobenzyl)phenyl]-2-propenoate

10 The benzyl bromide (500 mg) of example 1, step 2 was treated with 3,4-dichlorobenzenboronic acid according to the same procedure described in step 3 of example 1 to yield 410 mg of the title compound.

15 $^1\text{H NMR}$ (CDCl_3) δ 1.30 (3H, t), 4.03 (2H, s), 4.23 (2H, q), 6.28 (1H, d), 6.90 (1H, dd), 7.1-7.4 (5H, m), 7.57 (1H, d) and 7.89 (1H, d).

Step 2: (E)-3-[2-(3,4-dichlorobenzyl)phenyl]-2-propenoic acid

The hydrolysis of the previous ester (400 mg) was done according to Step 4 of example 1 to yield 296 mg of the title compound.

20 $^1\text{H NMR}$ (CDCl_3) δ 4.07 (2H, s), 6.31 (1H, d), 6.93 (1H, dd), 7.1-7.4 (5H, m), 7.50 (1H, d) and 7.99 (1H, d).

Step 3: N-[(E)-3-[2-(3,4-dichlorobenzyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (8)

25 The coupling reaction of the previous acid (170 mg; 0.55 mmol) was done according to step 5 of example 1 to yield 110 mg of the title compound.

30 $^1\text{H NMR}$ (CDCl_3) δ 4.07 (2H, s), 6.33 (1H, d), 6.85 (1H, d), 7.07 (3H, m), 7.24 (2H, m), 7.32 (1H, t), 7.53 (1H, d), 7.63 (1H, d), 7.88 (1H, d) and 7.97 (1H, d).

The acid was converted to the sodium salt with 1 equivalent of NaOH.

35 Elemental analysis calcd. for $\text{C}_{20}\text{H}_{14}\text{Cl}_2\text{NNaO}_3\text{S}_2 \cdot 1/2\text{H}_2\text{O}$: C, 49.7; H, 3.1; N, 2.9; S, 13.27; Found: : C, 49.46; H, 2.9; N, 2.86; S, 13.73;

5

EXAMPLE 5

N-((E)-3-{2-[(2-NAPHTHYLOXY)METHYL]PHENYL}-2-PROPENOYL)-2-
THIOPHENESULFONAMIDE (20)

Step 1: Ethyl (E)-3-{2-[naphthyloxy)methyl]phenyl}-2-propenoate

10 The benzyl bromide (250 mg, 0.93 mmol) of step 2 in example
1 and 2-naphthol (147 mg) in 5 mL of DMF were treated with cesium
carbonate (394 mg) at 40 °C for 12 h. The mixture was diluted with
EtOAc and washed with water and brine. The organic phase was dried
15 over Na₂SO₄, filtered and the solvent removed. Purification by silica gel
chromatography (10% EtOAc in hexane) yielded 245 mg of the title
compound.

¹H NMR (CDCl₃) δ 1.2 (3H, t), 4.22 (2H, q), 5.28 (2H, s), 6.41
(1H, d), 7.22 (2H, m), 7.3-7.5 (4H, m), 7.55 (1H, m), 7.64 (1H, m), 7.75 (3H,
m) and 8.05 (1H, d).

20

Step 2: (E)-3-{2-[naphthyloxy)methyl]phenyl}-2-propenoic acid

Hydrolysis of the previous ester (245 mg, 0.74 mmol) was
done according to step 4 of example 1 to yield 185 mg of the title
compound.

25 ¹H NMR (CDCl₃) δ 5.27 (2H, s), 6.45 (1H, d), 7.15-7.25 (2H, m),
7.32 (1H, t), 7.42 (3H, m), 7.55 (1H, d), 7.67 (1H, d), 7.77 (3H, m) and 8.11
(1H, d).

Step 3: N-((E)-3-{2-[(2-naphthyloxy)methyl]phenyl}-2-propenoyl)-2-
30 thiophenesulfonamide (20)

The coupling reaction of the previous acid (150 mg; 0.49
mmol) was done according to step 5 of example 1 to yield 77 mg of the title
compound.

35 ¹H NMR (CDCl₃) δ 5.2 (2H, s), 6.39 (1H, d), 7.02 (1H, s), 7.1-
7.2 (2H, m), 7.3-7.4 (4H, m), 7.53 (3H, m), 7.71 (3H, m), 7.83 (1H, s) and
8.07 (1H, d).

The product was converted to the sodium salt with 1
equivalent of NaOH.

- 5 Elemental analysis calcd. for $C_{24}H_{28}NNaO_4S_2 \cdot 3/2H_2O$: C, 57.82; H, 4.21; N, 2.81; Found: : C, 58.31; H, 3.96; N, 2.91.

EXAMPLE 6

- 10 N-[(E)-3-[2-(2-NAPHTHYLSULFINYL)PHENYL]-2-PROPENOYL]-2-
 THIOPHENESULFONAMIDE (21)

Step 1: 2-(2-naphthylthio)benzaldehyde

- A mixture of 2-thionaphthol (5.29 g; 33 mmol), 2-fluorobenzaldehyde (3.73 g; 33 mmol) and potassium carbonate (4.57 g; 33 mmol) in 28 mL of iso-propanol was heated to reflux for 12 h. The mixture was cooled to r.t., diluted with water and filtered. The solution was diluted with EtOAc and washed with water, brine and dry over $MgSO_4$. The crude product (7.9 g) was used as is for the next step.

- 1H NMR ($CDCl_3$) δ 7.07 (1H, d), 7.32 (2H, m), 7.42 (1H, d), 7.51 (2H, m), 7.78 (1H, m), 7.83 (2H, d), 7.88 (1H, s), 7.95 (1H, s) and 10.39 (1H, s).

Step 2: Ethyl (E)-3-[2-(2-naphthylthio)phenyl]-2-propenoate

- The previous aldehyde (7.72 g; 29.2 mmol) was converted to the ethyl ester according to step 1 of example 1 to furnish 6.36 g of the title compound.

1H NMR ($CDCl_3$) δ 1.24 (3H, t), 4.21 (2H, q), 6.36 (1H, d), 7.28 (4H, m), 7.42 (2H, m), 7.61 (1H, d), 7.72 (4H, m) and 8.28 (1H, d).

- 30 Step 3: Ethyl (E)-3-[2-(2-naphthylsulfinyl)phenyl]-2-propenoate

- The previous ester (3.00 g; 8.97 mmol) in 45 mL of dichloromethane was treated with 1.1 equivalent of mCPBA at 0 °C for 1 h. The mixture was quenched with sodium thiosulfite and extracted with EtOAc. The organic phase was dry over Na_2SO_4 and the crude purified by silica gel chromatography (30% EtOAc in hexane) to yield 2.35 g of the title compound.

1H NMR ($CDCl_3$) δ 1.34 (3H, t), 4.27 (2H, q), 6.26 (1H, d), 7.42 (2H, m), 7.53 (4H, m), 7.77 (2H, m), 7.88 (2H, m), 8.07 (2H, d), 8.22 (1H, s) and 8.28 (2H, m).

5

Step 4: Ethyl (E)-3-[2-(2-naphthylsulfinyl)phenyl]-2-propenoic acid

The previous ester (1.20 g; 3.43mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 1.08 g of the title compound.

10

¹H NMR (methanol-d₆) δ 6.23 (1H, d), 7.33 (1H, dd), 7.45 (3H, m), 7.53 (1H, t), 7.62 (1H, d), 7.8 (3H, m), 7.98 (1H, d), 8.05 (1H, d) and 8.27 (1H, s).

15

Step 5: 2-[(E)-3-[2-(2-naphthylsulfinyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (21)

The coupling reaction of the previous acid (500 mg; 1.55 mmol) was done according to step 5 of example 1 to yield 416 mg of the title compound.

20

¹H NMR (methanol-d₆) δ 6.19 (1H, d), 7.1 (1H, m), 7.22 (1H, dd), 7.45 (3H, m), 7.55 (2H, m), 7.67 (1H, d), 7.72-7.85 (4H, m), 7.99 (1H, d), 8.1 (1H, d) and 8.17 (1H, s).

25

The sodium salt was prepared with 1N NaOH. Elemental analysis calcd. for C₂₃H₁₆NNaO₄S₂·1/2H₂O: C, 55.36; H, 3.40; N, 2.81; S, 19.27; Found: : C, 55.00; H, 3.62; N, 2.81; S, 18.18.

EXAMPLE 7

N-[(E)-3-[2-(2-NAPHTHYLOXY)PHENYL]-2-PROPENOYL]-2-THIOPHENESULFONAMIDE (28)

30

Step 1: Ethyl (E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoate

2-fluoro benzaldehyde (3.0 g; 24.2 mmol), 2-naphthol (24.2 mmol) and potassium carbonate (26.6 mmol) were heated at reflux in dimethyl acetamide for 2 h. The mixture was cooled to r.t., diluted with EtOAc and washed with water and brine. The organic phase was dried over Na₂SO₄, filtered and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 3.4 g of the title compound.

35

5 ^1H NMR (CDCl_3) δ 6.93 (1H, d), 7.17-7.23 (1H, m), 7.28 (1H, dd), 7.37 (1H, s), 7.37 (3H, m), 7.7 (1H, d), 7.84 (2H, m), 7.94 (1H, d) and 10.53 (1H, s).

Step 2: Ethyl (E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoate

10 The previous aldehyde (2.00 g; 8.0 mmol) was converted to the title compound according to step 1 of example 1 to yield 2.52 g.

^1H NMR (CDCl_3) δ 1.25 (3H, t), 4.21 (2H, q), 6.55 (1H, d), 6.9 (1H, d), 7.15 (1H, t), 7.25 (3H, m), 7.42 (2H, m), 7.65 (2H, m), 7.83 (2H, t) and 8.02 (1H, d).

15

Step 3: (E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoic acid

The previous ester (2.52 g; 7.9 mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 1.57 g of the title compound.

20 ^1H NMR (CDCl_3) δ 6.62 (1H, d), 7.03 (1H, d), 7.2-7.5 (6H, m), 7.78 (1H, d) and 7.88-8.03 (4H, m). HRMS calcd. for $\text{C}_{19}\text{H}_{14}\text{O}_3 + \text{H}^+ = 291.1021$; Found: 291.1022.

Step 4: N-[(E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoyl]-2-

25 thiophenesulfonamide (28)

The coupling reaction of the previous acid (1.00 g; 3.4 mmol) was done according to step 5 of example 1 to yield 790 mg of the title compound.

30 ^1H NMR (CDCl_3) δ 6.91 (1H, d), 6.97 (1H, d), 7.15 (1H, dd), 7.24 (1H, t), 7.29 (1H, dd), 7.37 (1H, d), 7.40-7.55 (3H, m), 7.74-7.83 (2H, m), 7.92 (2H, m) and 7.99 (2H, m).

The sodium salt was prepared with 1N NaOH. HRMS calcd. for $\text{C}_{23}\text{H}_{16}\text{NNaO}_4\text{S}_2 + \text{H}^+ = 458.0497$; Found: 458.0497.

35

EXAMPLE 8

THIOPHENE-2-SULFONYL CARBAMIC ACID [2-(2-NAPHTHYLSULFONYL)PHENYL]METHYL ESTER (31)

Step 1: [2-(2-naphthylthio)phenyl]methanol

5 To 2-(2-naphthylthio) benzaldehyde (7.24 g; 27.4 mmol from Example 6, step 1) in 70 mL of methanol and 30 mL of THF at 0 °C was added NaBH₄ (54.8 mmol) portionwise. After 1h at 0 °C, the solution was brought to r.t. and quenched with water. After dilution with EtOAc, the solution was washed with water and brine. The organic phase was dry
10 over Na₂SO₄, filtered and the crude purified by silica gel chromatography to yield 6.71 g of the title compound.

¹H NMR (acetone-d₆) δ 4.29 (1H, t), 4.7 (2H, d), 7.29 (2H, m), 7.35-7.52 (4H, m), 7.71 (2H, m), 7.77 (1H, m) and 7.83 (2H, m).

15 Step 2: [2-(2-Naphthylsulfonyl)phenyl]methanol

To the previous sulfide (500 mg; 1.88 mmol) in 8 mL of dichloromethane at 0 °C was added m-CPBA (5.64 mmol) and let stirred for 2 h. The mixture was diluted with EtOAc and washed with NaOH (1N) and brine. The organic phase was dry over Na₂SO₄, filtered and the
20 crude purified by silica gel chromatography (40% EtOAc in hexane) to yield 390 mg of the title compound.

¹H NMR (acetone-d₆) δ 4.37 (1H, t), 4.9 (2H, d), 7.57 (1H, dt), 7.65-7.80 (4H, m), 7.82 (1H, d), 8.0-8.1 (2H, m), 8.2 (2H, m) and 8.63 (1H, s).

25

Step 3: 2-Thiophenesulfonyl isocyanate

A mixture of 2-thiophenesulfonylamide (1.5 g) and oxalyl chloride (6 mL) in 10 mL of 1,2-dichloroethane was refluxed for 14h. The solvent was removed under vacuum and the crude used as is for the
30 next step.

Step 4:

To the alcohol of step 2 (250 mg; 0.84 mmol) in ether at 0 °C was added the previous isocyanate (2 equivalent) and let stirred 1h at 0
35 °C. The solution was quenched with water and extracted with EtOAc. The organic phase dry over Na₂SO₄, filtered and the crude purified by silica gel chromatography (5% CH₃OH in CH₂Cl₂) to yield 300 mg of the title compound.

- 5 ¹H NMR (CDCl₃) δ 5.55 (2H, s), 7.08 (1H, m), 7.55-7.72 (6H, m), 7.82 (2H, m), 8.0 (1H, d), 8.07 (1H, d), 8.2 (2H, m) and 8.66 (1H, s).
The sodium salt was prepared with 1N NaOH.
Elemental analysis calcd. for C₂₂H₁₆NNaO₆S₃·2H₂O: C, 48.44;
H, 3.67; N, 2.57; S, 17.63;
10 Found: : C, 48.86; H, 3.13; N, 2.63; S, 16.46.

5

EXAMPLE 9

N-([2-[2-(2-NAPHTHYLMETHYL)PHENYL]CYCLOPROPYL]
CARBONYL-2-THIOPHENESULFONAMIDE (45)

Step 1: Ethyl 2-[2-(2-naphthylmethyl)phenyl]-1-cyclopropanecarboxylate

10

The ethyl ester (300 mg; 0.95 mmol) of step 1 in example 3 and Pd(OAc)₂ (10 mg) were treated with diazomethane at 0° C for 1h. The solvent was removed and the crude oil purified by silica gel chromatography (5% EtOAc in hexane) to yield 300 mg of the title compound.

15

¹H NMR (CDCl₃) δ 1.1 (3H, t), 1.27 (1H, m), 1.45 (1H, m), 1.7 (1H, m), 2.53 (1H, m), 3.98 (2H, m), 4.29 (2H, s), 7.0 (1H, m), 7.18 (3H, m), 7.27 (1H, m), 7.39 (2H, m), 7.48 (1H, s) and 7.75 (3H, m).

Step 2: 2-[2-(2-naphthylmethyl)phenyl]-1-cyclopropanecarboxylic acid

20

The previous ester (300 mg; 0.91 mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 230 mg of the title compound.

¹H NMR (CDCl₃) δ 1.45 (1H, m), 1.6 (1H, m), 1.8 (1H, m), 2.67 (1H, m), 4.33 (2H, s), 7.1 (1H, m), 7.24 (4H, m), 7.41 (2H, m), 7.58 (1H, s) and 7.78 (3H, m).

25

Step 3: N-([2-[2-(2-naphthylmethyl)phenyl]cyclopropyl]carbonyl-2-thiophenesulfonamide (45)

The coupling reaction of the previous acid (230 mg; 0.76 mmol) was done according to step 5 of example 1 to yield 100 mg of the title compound.

¹H NMR (CDCl₃) δ 1.32 (1H, m), 1.48 (1H, m), 1.63 (1H, m), 2.6 (1H, m), 4.13 (2H, s), 6.97 (2H, m), 7.12 (4H, m), 7.38 (3H, m), 7.52 (1H, d), 7.65 (2H, m) and 7.79 (2H, m). The sodium salt was prepared with 1N NaOH. Elemental analysis calcd. for C₂₅H₂₀NNaO₃S₂·1/2H₂O: C, 62.75; H, 4.39; N, 2.93; S, 13.4; Found: : C, 62.25; H, 4.24; N, 3.02; S, 12.15.

35

5

EXAMPLE 10

N-((E)-3-(2-(6-BENZYLOXY-2-NAPHTHYL)METHYL)PHENYL)-2-PROPENOYL)-5-BROMO-2-METHOXYBENZENESULFONAMIDE (46)

(E)-3-(2-(6-benzyloxy-2-naphthyl)methyl)phenyl)-2-propenoic acid

10

Step 1: [(6-bromo-2-naphthyl)oxy](phenyl)methane

To a mixture of 6-bromo-2-naphthol (1.99 g, 8.9 mmol) and benzyl bromide (1.2 ml, 1.1 equiv.) in DMF (18 ml) at 0°C was added a suspension of NaH 80% in oil (324 mg, 1.2 equiv.) and the mixture was stirred at 0°C for an hour and at r.t. for another hour. After addition of half saturated NH₄Cl, the product was extracted in i-PrOAc, washed with 1 N HCl, dried over Na₂SO₄ and concentrated to yield 2.84 g of an oil.

15

Step 2: 6-benzyloxy-2-naphthaleneboronic acid

To a solution of the previous bromide (940 mg, 3.00 mmol) in THF (15 ml) at -78°C was added n-BuLi 1.6 M in hexanes (2.2 ml, 1.2 equiv.) and the mixture was stirred at -78°C for 15 min. Tri-isopropyl borate (0.97 ml, 1.4 equiv.) was added and the reaction mixture was warmed to r.t. After addition of 2 N HCl, the product was extracted in EtOAc, dried over Na₂SO₄ and concentrated to yield a solid. This solid was washed with ether:hexane 1:1 to yield 679 mg of pure material.

20

¹H NMR (Acetone-d₆:DMSO-d₆) δ 5.27 (2H, s), 7.22 (1H, dd), 7.33 (1H, dd), 7.40 (3H, m), 7.54 (2H, d), 7.63 (2H, s), 7.72 (1H, d), 7.83 (1H, d), 7.90 (1H, d), 8.36 (1H, s).

25

Step 3: Ethyl (E)-3-(2-[(6-benzyloxy)-2-naphthyl]methyl)phenyl)-2-propenoate

A mixture of the previous boronic acid (1.05 g, 3.8 mmol), Pd(Ph₃P)₄ (185 mg), the benzylic bromide of step 2 in example 1 (1.07 g, 4.0 mmol), 2 M aq. Na₂CO₃ (4 ml) and toluene (8 ml) was degazed and stirred at 100°C under nitrogen for 4 h. After addition of half saturated NH₄Cl, the product was extracted in EtOAc, dried over Na₂SO₄ and concentrated. Purification by flash chromatography with EtOAc:toluene:hexane 2.5:75:25 yielded 1.17 g of the title compound as an oil.

30

35

5

Step 4: (E)-3-(2-([6-(benzyloxy)-2-naphthyl]methyl)phenyl)-2-propenoic acid

The previous ester was hydrolyzed according to the procedure of step 4 of example 1 to yield the title compound.

10

Step 5: 5-Bromo-2-methoxybenzenesulfonamide

To 5-bromo-2-methoxybenzenesulfonyl chloride (45g; 157.6 mmol, from Lancaster Chemical) at 0°C in THF, was added concentrated NH₄OH (42.5 mL) and the reaction mixture was brought to r.t. for 2 h. The reaction mixture was diluted with EtOAc, extracted with NaHCO₃ (2X), brine, and the organic phase was dried over MgSO₄. The solvent was removed to give the title compound.

15

Step 6: N-((E)-3-(2-(6-benzyloxy-2-naphthyl)methyl)phenyl)-2-propenoyl)-5-bromo-2-methoxybenzenesulfonamide (46)

20

To the acid from step 5 (190 mg, 0.482 mmol) in CH₂Cl₂ was added DMF (10 µL) and oxalyl chloride (60 µL) at 0°C and the mixture was warmed to r.t. for an hour and concentrated to dryness. The resulting acid chloride was redissolved in CH₂Cl₂:THF 1:1 (10 mL) and 5-bromo-2-methoxybenzenesulfonamide (154 mg, 1.2 equiv., from step 6) and Et₃N (135 µL, 2 equiv.) were added at 0°C. The mixture was then warmed to r.t. for an hour, 0.5 N HCl was added and the product was extracted in i-PrOAc, dried over Na₂SO₄ and purified by flash chromatography with EtOAc:toluene:acetic acid 20:80:1 to yield 93 mg of a white solid.

25

30

¹H NMR (CDCl₃) δ

MS (APCI, neg.) 643.3, 641.8, 640.0 (M-1), 393.2.

EXAMPLE 11

N-((E)-3-[2-NAPHTHYLMETHYL]PHENYL)-2-PROPENOYL)-5-BROMO-2-METHOXY-1-BENZENESULFONAMIDE (301)

35

Step 1: N-((E)-3-[2-naphthylmethyl]phenyl)-2-propenoyl)-5-bromo-2-methoxy-1-benzenesulfonamide (301)

5 The carboxylic acid (400 mg; 1.22 mmol) of example 3 step 2 was coupled with 5-bromo-2-methoxy-1-benzenesulfonyl chloride according to the procedure of step 5 in example 1 to yield 284 mg of the title compound.

¹H NMR (acetone-d₆-DMSO-d₆) δ 3.85 (3H, s), 4.31 (2H, s),
10 6.65 (1H, d), 7.15 (1H, d), 7.3 (1H, m), 7.35-7.50 (4H, m), 7.55-7.65 (2H, m), 7.7-7.9 (5H, m) and 8.01 (1H, d).

 The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C₂₇H₂₁BrNNaO₄S.1/2H₂O: C, 57.15; H, 3.88; N, 2.47; Found: : C, 56.88; H, 3.73; N, 2.52.

15

EXAMPLE 12

N-[(E)-3-[5-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL]-2-THIOPHENESULFONAMIDE (303)

20 Step 1: 5-chloro-2-methylbenzaldehyde

 To a solution of 2-bromo-4-chlorotoluene (20.0 g; 97.3 mmol) in 300 mL of THF at -78 °C was added dropwise a 2.5 M solution of n-BuLi (102.2 mmol). After 30 min of stirring at that temperature, 1-formylpiperidine (11.4 mL) in 10 mL of THF was added and the solution
25 left for 1 h. It was brought to 0 °C , quenched with NH₄OAc (25%) and diluted with EtOAc. The organic phase was dried over Na₂SO₄, filtered and the solvent removed to yield 13.3 g of the title compound.

¹H NMR (CDCl₃) δ 2.6 (3H, s), 7.15 (1H, d), 7.4 (1H, d), 7.75 (1H, s) and 10.2 (1H, s).

30

Step 2: Ethyl (E)-3-(5-chloro-2-methylphenyl)-2-propenoate

 The previous aldehyde (13.3 g; 86.0 mmol) was converted to the ethyl cinnamate according to step 1 of example 1 to yield 16.67 g.

¹H NMR (CDCl₃) δ 1.2 (3H, t), 2.26 (3H, s), 4.15 (2H, q), 6.21
35 (1H, d), 6.99 (1H, d), 7.13 (2H, m), 7.39 (1H, s) and 7.73 (1H, d).

Step 3: Ethyl (E)-3-[2-(bromomethyl)-5-chlorophenyl]-2-propenoate

5 The previous ester (16.66 g; 74.1 mmol) was converted to the benzylic bromide according to step 2 of example 1 to yield 9.0 g of the title compound.

^1H NMR (CDCl_3) δ 1.2 (3H, t), 4.25 (2H, q), 4.5 (2H, s), 6.4 (1H, d), 7.28 (2H, s), 7.55 (1H, s) and 7.95 (1H, d).

10

Step 4: Ethyl (E)-3-[5-chloro-2-(2-naphthylmethyl)phenyl]-2-propenoate

The previous benzylic bromide was coupled in a Suzuki type reaction with 2-naphthylboronic acid according to step 3 of example 1 to yield 1.14 g of the title compound.

15 ^1H NMR (CDCl_3) δ 1.15 (3H, t), 4.09 (2H, q), 4.12 (2H, s), 6.2 (1H, d), 7.03 (1H, d), 7.15 (2H, m), 7.3 (2H, m), 7.37 (1H, s), 7.45 (1H, s), 7.65 (3H, m) and 7.87 (1H, d).

Step 5: (E)-3-[5-chloro-2-(2-naphthylmethyl)phenyl]-2-propenoic acid

20 The hydrolysis of the previous ester (1.14 g) was done according to Step 4 of example 1 to yield 0.99 g of the title compound.

^1H NMR (CDCl_3) δ 4.23 (2H, s), 6.31 (1H, d), 7.12 (1H, d), 7.22 (1H, m), 7.3 (1H, m), 7.42 (2H, m), 7.48 (1H, s), 7.59 (1H, s), 7.75 (3H, m) and 8.05 (1H, d).

25

Step 6: N-[(E)-3-[5-chloro-2-(2-naphthylmethyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (303)

30 The coupling reaction of the previous acid (400 mg; 1.22 mmol) was done according to step 5 of example 1 to yield 272 mg of the title compound.

^1H NMR (acetone-d_6) δ 4.25 (2H, s), 6.58 (1H, d), 7.0 (1H, t), 7.23 (2H, m), 7.33 (1H, m), 7.39 (2H, m), 7.5-7.6 (2H, m), 7.55 (5H, m) 7.86 (1H, m) and 8.04 (1H, d).

35 The product was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for $\text{C}_{24}\text{H}_{17}\text{ClNNaO}_3\text{S}_2 \cdot 1/2\text{H}_2\text{O}$: C, 57.76; H, 3.64; N, 2.81; S, 12.84; Found: : C, 57.78; H, 3.62; N, 2.86; S, 12.85.

5

EXAMPLE 13

(E)-3-[4-CHLORO-2-[6-FLUORO-2-NAPHTHYL)METHYL]PHENYL]-2-
PROPENOIC ACID SODIUM SALT (457)

Step 1: Ethyl (E)-3-(5-chloro-2-methylphenyl)-2-propenoate

10 To 2-bromo-4-chloro toluene (20.0g; 97.3 mmol) in 300 mL of THF at -78 °C was added n-BuLi 2.5 M (40.8 mL) dropwise. After 20 min. 1-formylpiperidine (11.4 mL; 103.0 mmol) in 10 mL of THF was added dropwise. After 30 min the reaction mixture was brought to 0°C and quenched with HCl (10%) and diluted with EtOAc. The organic
15 phase was collected, dry and the solvent evaporated to yield 13.3g (89%) of 5-chloro-2-methylbenzaldehyde. This crude aldehyde was mixed with 1.1 equivalent of triethyl phosphonoacetate in THF. Sodium hydride 80% (1.3 equivalent) was added portionwise and 1 h later the reaction was quenched with 25% NH₄Cl. The reaction mixture was diluted with
20 EtOAc and the organic phase collected, dried and the solvent removed. The crude oil was purified on a short pad of silica gel using 5% EtOAc in hexane to afford 16.67 g of the title compound.

Alternatively, this procedure can be done in one reaction vessel. At the end of the first step, the flask is brought to rt and
25 the phosphonoacetate in THF is added.

¹H NMR (CDCl₃) δ 1.21 (3H, t), 2.27 (3H, s), 4.15 (2H, q), 6.22 (1H, d), 6.95-7.15 (3H, m), 7.40 (1H, s) and 7.75 (1H, d).

Step 2: Ethyl(E)-3-[2-(bromomethyl)-5-chlorophenyl]-2-propenoate

30 The bromination was done according to step 2 of example 1 to provide the title compound in 45% yield.

¹H NMR (CDCl₃) δ 1.32 (3H, t), 4.27 (2H, q), 4.52 (2H, s), 6.43 (1H, d), 7.30 (2H, s), 7.55 (1H, s) and 7.93 (2H, d).

35 Step 3: 6-Fluoro-2-naphthol

A solution of 2-(4-fluorophenyl)acetyl chloride (5.0g; 29 mmol) in CH₂Cl₂ was added to AlCl₃ (7.73g; 58 mmol) in CH₂Cl₂ at -20 °C over 30 min. Trimethylsilyl acetylene (9.96g; 101.43 mmol) was added also over 30 min and stirred at -10 °C for 1h. The mixture was poured in

- 5 ice and extracted with EtOAc. The organic phase was washed with water, NaHCO₃ and brine. After purification by gel silica chromatography (10% EtOAc in hexane) 2.43 g (36%) of 3-(trimethylsilyl)-6-chloro-2-naphthol was collected. The desilylation was done with TFA in CH₂Cl₂ at rt overnight. Purification by gel silica chromatography (10% EtOAc in hexane) afforded the title compound in 69% yield.

¹H NMR (CDCl₃) δ 7.10-7.20 (3H, m), 7.37 (1H, dd) and 7.65 (2H, m).

15 Step 4: Ethyl (E)-3-[4-chloro-2-[(6-fluoro-2-naphthyl)methyl]phenyl]-2-propenoate

- The naphthol of Step 3 was converted to the triflate with triflic anhydride/pyridine in CH₂Cl₂ at 0 °C. This was coupled with the organozinc of the benzyl bromide of step 2 in example 13, with dppf and Pd(dba)₂. This yielded the title compound in 47% yield after purification by silica gel chromatography (10% EtOAc in hexane).

¹H NMR (CDCl₃) δ 1.25 (3H, t), 4.20 (2H, q), 6.30 (1H, d), 7.10-7.27 (4H, m), 7.38 (1H, dd), 7.48 (1H, s), 7.57 (1H, dd), 7.66 (2H, m) and 7.95 (1H, d).

25 Step 5: (E)-3-[4-Chloro-2-[(6-fluoro-2-naphthyl)methyl]phenyl]-2-propenoic acid, sodium salt

The hydrolysis of the ester of Step 4 (1.03g; 2.7 mmol) was done according to step 4 of example 1 to yield 800mg (87%) of the title compound. The sodium salt was prepared with 1N NaOH.

- 30 ¹H NMR (CDCl₃) δ 4.21 (2H, s), 6.30 (1H, d), 7.10-7.40 (4H, m), 7.38 (1H, dd), 7.45 (1H, s), 7.58 (1H, d), 7.68 (2H, m) and 8.05 (1H, d).

LRMS for M-1= 339.

EXAMPLE 14

- 35 5-BROMO-N((E)-3-[5-CHLORO-2-[(6-FLUORO-2-NAPHTHYL-2)METHYL]PHENYL]-2-PROPENOYL)-2-METHOXYBENZENESULFONAMIDE SODIUM SALT (378)

5 Step 1: 5-Bromo -N-((E)-3-{5-chloro-2-[(6-fluoro-2-naphthyl)methyl]phenyl}-2-propenoyl)-2-methoxybenzenesulfonamide

The coupling reaction of the acid of Example 1 Step 5 with 5-bromo-2-methoxybenzenesulfonamide (500 mg; 1.47 mmol) was done according to step 5 of example 1 to yield 662 mg (77%) of the title
10 compound. The sodium salt was prepared with 1N NaOH.

¹H NMR (DMSO-d₆) δ 3.78 (3H, s), 4.22 (2H, s), 6.53 (1H, d), 7.17 (1H, d), 7.27 (1H, d), 7.35 (2H, m), 7.47 (1H, dd), 7.51 (1H, s), 7.58 (1H, d), 7.64 (1H, dd) and 7.75-7.90 (5H, m).

LRMS for M-1= 588.

15

EXAMPLE 15

(E)-3-{5-CHLORO-2-[(6-CHLORO-2-NAPHTHYL)METHYL]PHENYL}-2-
PROPENOIC ACID SODIUM SALT (469)

20 Step 1: 6-Chloro-2-naphthol

The title compound was prepared from 2-(4-fluorophenyl)acetyl chloride according to step 3 of example 13.

¹H NMR (CDCl₃) δ 7.10 (2H, m), 7.34 (1H, dd), 7.55-7.67 (2H, m) and 7.72 (1H, s).

25

Step 2: Ethyl (E)-3-{5-chloro-2-[(6-chloro-2-naphthyl)methyl]phenyl}-2-propenoate

The title compound was prepared according to step 4 of example 13 in 30% yield.

30 ¹H NMR (CDCl₃) δ 1.23 (3H, t), 4.20 (4H, m), 6.29 (1H, d), 7.10 (1H, d), 7.22 (2H, m), 7.33 (1H, dd), 7.42 (1H, s), 7.53 (1H, d), 7.61 (2H, d), 7.70 (1H, s) and 7.91 (1H, d).

Step 3: (E)-3-{5-Chloro-2-[(6-chloro-2-naphthyl)methyl]phenyl}-2-propenoic acid, sodium salt

35

The hydrolysis of the ester of Step 2 (620 mg; 1.6 mmol) was done according to step 4 of example 1 to yield 500mg (87%) of the title compound.

5 ^1H NMR (CDCl_3) δ 4.22 (2H, s), 6.30 (1H, d), 7.15 (1H, d),
7.20-7.39 (3H, m), 7.43 (1H, s), 7.56 (1H, s), 7.62 (2H, t), 7.75 (1H, s) and
8.02 (1H, d).

Elemental analysis calcd for $\text{C}_{20}\text{H}_{13}\text{Cl}_2\text{NaO}_2 \cdot \text{H}_2\text{O}$: C, 60.48;
10 H, 3.78; Found C, 60.68, H, 3.63.

5

EXAMPLE 16

5-BROMO-N-((E)-3-{5-CHLORO-2-[(6-CHLORO-2-NAPHTHYL-
2)METHYL]PHENYL}-2-PROPENOYL)-2-
METHOXYBENZENESULFONAMIDE, SODIUM SALT (450)

10 Step 1: 5-Bromo -N-((E)-3-{5-chloro-2-[(6-chloro-2-
naphthyl)methyl]phenyl}-2-propenoyl)-2-methoxybenzenesulfonamide

The coupling reaction of the acid of Example 15 Step 3 (500 mg; 1.4 mmol) was done according to step 5 of example 1 with 5-bromo-2-methoxybenzenesulfonamide to yield 662 mg (74%) of the title compound.

15 The sodium salt was prepared with 1N NaOH.

¹H NMR (DMSO-d₆) δ 3.78 (3H, s), 4.22 (2H, s), 6.53 (1H, d), 7.20 (1H, d), 7.30-7.40 (2H, m), 7.45 (2H, m), 7.55 (1H, s), 7.59 (1H, s), 7.79 (3H, m), 7.85-7.92 (2H, m) and 7.98 (1H, d).

Elemental analysis calcd for C₂₇H₁₉BrCl₂NNaO₄S .2H₂O :

20 C, 49.01; H, 3.33; N, 2.14; Found C, 48.89, H, 3.47; N, 2.11.

EXAMPLE 17

(E)-3-(5-CHLORO-2-[(6-DIFLUOROMETHOXY)-2-
NAPHTHYL]METHYL]PHENYL)-2-PROPENOIC ACID, SODIUM SALT
25 (505)

Step 1: 6-Bromo-2-difluoromethoxynaphthalene

Methyl chlorodifluoroacetate (5.3 mL) was added dropwise to 6-bromonaphthol (10.25 g; 45.9 mmol) and potassium carbonate (7.61g; 30 55.1 mmol) at 90 °C in 160 mL of DMF for 6 h. Purification by gel silica chromatography (3% EtOAc in hexane) gave 4.80 g (38%) of the title compound.

¹H NMR (CDCl₃) δ 6.61 (1H, t), 7.31 (1H, dd), 7.48 (1H, d), 7.56 (1H, dd), 7.67 (1H, d), 7.72 (1H, d) and 8.01 (1H, d).

35

Step 2: Ethyl (E)-3-(5-chloro-2-[(6-difluoromethoxy)-2-
naphthyl]methyl]phenyl)-2-propenoate

5 The corresponding boronic acid of the previous halide was coupled according to step 3 of example 1 of the title compound in 57% yield.

¹H NMR (CDCl₃) δ 1.25 (3H, t), 4.22 (4H, m), 6.28 (1H, d), 6.53 (1H, t), 7.11 (1H, d), 7.25 (2H, m), 7.45 (2H, d), 7.55 (1H, d), 7.72 (2H, t)
10 and 7.92 (1H, d).

Step 3: (E)-3-(5-Chloro-2-([6-difluoromethoxy]-2-naphthyl)methyl)phenyl)-2-propenoic acid, sodium salt

 The hydrolysis of the ester of Step 2 (1.9 g; 4.7 mmol) was
15 done according to step 4 of example 1 to yield 600mg of the title compound.

¹H NMR of sodium salt (DMSO-d₆) δ 4.20 (2H, s), 6.29 (1H, d), 7.10-7.40 (6H, m), 7.58 (3H, m) and 8.84 (2H, t).

 HRMS calc'd for C₂₁H₁₄O₃F₂ClNa +H= 411.0575; Found:
20 411.0577.

EXAMPLE 18

5-BROMO-N-[(E)-3-(5-CHLORO-2-([6-DIFLUOROMETHOXY]-2-NAPHTHYL_METHYL)-2-PROPENOYL)-2-METHOXYBENZENESULFONAMIDE, SODIUM SALT (447)
25 METHOXYBENZENESULFONAMIDE, SODIUM SALT (447)

Step 1: 5-Bromo -N-[(E)-3-(5-chloro-2-([6-difluoromethoxy]-2-naphthyl)methyl)phenyl)-2-propenoyl]-2-methoxybenzenesulfonamide

 The coupling reaction of the acid of Example 17 Step 3
30 (1.00g; 2.57 mmol) was done according to step 5 of example 1 with 5-bromo-2-methoxybenzenesulfonamide to yield 915 mg (56%) of the title compound. The sodium salt was prepared with 1N NaOH.

¹H NMR of sodium salt DMSO-d₆) δ 3.66 (3H, s), 4.18 (2H, s), 6.36 (1H, d), 6.92 (1H, d), 7.20-7.35 (5H, m), 7.48 (2H, m), 7.55-7.65 (3H, m) and 7.80 (3H, m).
35 m) and 7.80 (3H, m).

 LRMS for M-1= 634.

5 ^1H NMR (DMSO- d_6) δ 3.85 (3H, s), 4.10 (2H, s), 6.54 (1H, s),
7.01 (1H, d), 7.22 (1H, d), 7.32 (2H, m), 7.40-7.50 (2H, m), 7.56 (1H, s), 7.67
(1H, d), 7.86 (1H, d), 7.91 (1H, s) and 12.37 (1H, s).

LRMS for M-1= 586.

10

EXAMPLE 21

5-BROMO-N-[(E)-3-[4-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2-
PROPENOYL]-2-METHOXYBENZENESULFONAMIDE, SODIUM SALT
(449)

15 Step 1: Ethyl (E)-3-[4-chloro-2-[(2-naphthylmethyl)phenyl]-2-propenoate

2-Bromo-5-chloro toluene (20.0 g) was converted to the
corresponding aldehyde and then to the cinnamate according to step 1 of
example 13. This cinnamate was converted to the benzylic bromide
according to step 2 of example 1 and coupled via a Suzuki coupling
20 reaction according to step 3 of example 1 with naphthalene boronic acid
to yield the title compound.

^1H NMR (CDCl_3) δ 1.30 (3H, t), 4.22 (4H, m), 6.29 (1H, d),
7.15-7.27 (3H, m), 7.42 (2H, m), 7.52 (2H, m), 7.75 (3H, m) and 7.99 (1H, d).

25 Step 2: (E)-3-[4-Chloro-2-[(2-naphthylmethyl)phenyl]-2-propenoic acid
(530)

The hydrolysis of the ester of Step 1 (0.56 g; 1.57 mmol) was
done according to step 4 of example 1 to yield 450 mg (88%) of the title
compound.

30 ^1H NMR (CDCl_3) δ 4.24 (2H, s), 6.30 (1H, d), 7.20-7.30 (3H,
m), 7.42 (2H, m), 7.51 (2H, m), 7.75 (3H, m) and 8.09 (1H, d).

LRMS for M-1= 321.

35 Step 3: 5-Bromo-N-[(E)-3-[4-chloro-2-(2-
naphthylmethyl)phenyl]propenoyl]-2-methoxybenzenesulfonamide

The coupling reaction of the acid of Step 2 (0.296 g; 0.89
mmol) was done according to step 5 of example 1 with 5-bromo-2-
methoxybenzenesulfonamide to yield 213 mg (42%) of the title compound.
The sodium salt was prepared with 1N NaOH.

5 ¹H NMR (ACETONE-MEOH-d₆) δ 3.70 (3H, s), 4.20 (2H, s),
6.44 (1H, d), 6.95 (2H, m), 7.25 (3H, m), 7.40 (2H, m), 7.55 (3H, m), 7.75
(3H, m), 7.95 (1H, d) and 8.02 (1H, d).

LRMS for M-1= 568.

5

EXAMPLE 22

(E)-3-[5-METHOXY-2-(2-NAPHTHMETHYL)PHENYL]-2-PROPENOIC
ACID, SODIUM SALT (534)

Step 1: (2-Bromo-4-methoxyphenyl)(2-naphthyl)methanone

10 AlCl₃ (17.48 g; 131.1 mmol) was added portionwise to a mixture of 3-bromocresol (16.04 g; 87.4 mmol) and 2-naphthoyl chloride (25.00 g; 131.1 mmol) in 50 mL of CHCl₃ gave 14.0 g (47%) of the title compound.

¹H NMR (CDCl₃) δ 3.78 (3H, s), 6.92 (1H, dd), 7.19 (1H, d),
15 7.38 (1H, d), 7.50 (1H, t), 7.59 (1H, t), 7.89 (3H, m), 7.95 (1H, dd) and 8.18 (1H, s).

Step 2: 2-(2-Bromo-4-methoxybenzyl)naphthalene

 To the methanone of Step 1 (14.0 g) and triethylsilane (15
20 mL) in 15 mL of CHCl₃ was added TFA and was heated to 50°C overnight. The solution was cooled and quenched with NaOH (2N) to provide the title compound in 82% yield.

¹H NMR (CDCl₃) δ 3.75 (3H, s), 4.20 (2H, s), 6.75 (1H, dd),
25 7.07 (1H, d), 7.12 (1H, s), 7.30 (1H, d), 7.42 (2H, m), 7.58 (1H, s) and 7.76 (3H, m).

Step 3: Ethyl (E)-3-[5-methoxy-2-(2-naphthylmethyl)phenyl]-2-propenoate

 The naphthalene of Step 2 was converted to the
30 corresponding aldehyde according to the step 1 of example 13 in 98% yield. This aldehyde was then converted to the cinnamate according to step 1 of example 13 in 90% yield.

¹H NMR (CDCl₃) δ 3.70 (3H, s), 4.11 (4H, m), 6.20 (1H, d),
6.77 (1H, dd), 6.99 (1H, d), 7.03 (1H, d), 7.15 (1H, d), 7.30 (2H, m), 7.39 (1H,
35 s), 7.60-7.70 (3H, m) and 7.90 (1H, s).

Step 4: (E)-3-[5-Methoxy-2-(2-naphthmethyl)phenyl]-2-propenoic acid

5 The hydrolysis of the ester of Step 3 (2.83 g; 8.2 mmol) was done according to step 4 of example 1 to yield 2.16 g (83%) of the title compound. The sodium salt was prepared with 1N NaOH.

1H NMR (CDCl₃) δ 3.70 (3H, s), 4.13 (2H, s), 6.20 (1H, d), 6.80 (1H, dd), 7.02 (2H, m), 7.15 (1H, d), 7.29 (2H, m), 7.39 (1H, s), 7.62 (3H, m) and 8.03 (1H, d).

LRMS calcd for M-1= 317.

15

EXAMPLE 23

5-BROMO-2-METHOXY-N-[(E)-3-[5-METHOXY-2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL]BENZENESULFONAMIDE SODIUM SALT (448)

20 Step 1: 5-Bromo-2-methoxy-N-[(E)-3-[5-methoxy-2-(2-naphthylmethyl)phenyl]-2-propenoyl]benzenesulfonamide

The coupling reaction of the acid of Example 22 Step 4 (0.600 g; 1.88 mmol) was done according to step 5 of example 1 with 5-bromo-2-methoxybenzenesulfonamide to yield 573 mg (57%) of the title compound.

25 The sodium salt was prepared with 1N NaOH.

1H NMR (CDCl₃) δ 3.72 (3H, s), 3.77 (3H, s), 4.13 (2H, s), 6.40 (1H, d), 6.70 (1H, d), 6.85 (1H, dd), 7.02 (1H, d), 7.10-7.20 (2H, m), 7.37 (3H, m), 7.57 (1H, dd), 7.60-7.80 (3H, m), 7.95 (1H, d), 8.15 (1H, d) and 9.12 (1H, broad s).

30

LRMS calcd for M-1= 564.

EXAMPLE 24

(E)-3-[5-CHLORO-2-(4-CHLOROBENZYL)PHENYL]-2-PROPENOIC ACID SODIUM SALT (537)

35

Step 1: Ethyl(E)-3-[5-chloro-2-(4-chlorobenzyl)phenyl]-2-propenoate

5 The benzyl bromide of step 2 of example 13 was coupled in a Suzuki coupling reaction with 4-chlorobenzene boronic acid according to the procedure of step 2 example 1 to yield 69% of the title compound.

¹H NMR (CDCl₃) δ 1.30 (3H, t), 4.02 (2H, s), 4.22 (2H, q), 6.29 (1H, d), 6.99 (2H, d), 7.08 (1H, d), 7.20-7.30 (3H, m), 7.52 (1H, s) and 7.83
10 (1H, d).

Step 2: (E)-3-[5-Chloro-2-(4-chlorobenzyl)phenyl]-2-propenoic acid

 The hydrolysis of the ester of Step 1 (1.14 g; 3.4 mmol) was done according to step 4 of example 1 to yield 860 mg (83%) of the title
15 compound. The sodium salt was prepared with 1N NaOH.

¹H NMR (CDCl₃) δ 4.04 (2H, s), 6.30 (1H, d), 7.00 (2H, d), 7.10 (1H, d), 7.23 (2H, d), 7.29 (1H, d), 7.55 (1H, s) and 7.95 (1H, d).

 LRMS calcd for M-1= 305.

20

EXAMPLE 25

(E)-3-{2-[(5-(PHENYLMETHOXY)INDOLYL)METHYL]-5-
FLUOROPHENYL}-N-[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-
2-PROPENAMIDE (451)

25

Step 1: Ethyl (E)-3-(5-fluoro-2-methylphenyl)-2-propenoate

 5-Fluoro-2-methylbenzaldehyde (40.58 g; 294 mmol) was converted to the ethyl cinnamate according to step 1 of example 1 to yield 40.81 g. of the title compound.

30 ¹H NMR (acetone-d₆) δ 1.29 (3H, t), 2.40 (3H, s), 4.23 (2H, q), 6.49 (1H, d), 7.07 (1H, td), 7.29 (1H, dd), 7.46 (1H, dd) and 7.87 (1H, dd).

Step 2: Ethyl (E)-3-[2-(bromomethyl)-5-fluorophenyl]-2-propenoate

 The ester of Step 1 (40.80 g; 196 mmol) was converted to the benzylic bromide according to step 2 of example 1 to yield 24.17 g of the
35 title compound.

¹H NMR (acetone-d₆) δ 1.30 (3H, t), 4.24 (2H, q), 4.81 (2H, s), 6.62 (1H, d), 7.18 (1H, td), 7.58 (2H, m) and 8.02 (1H, dd).

5 Step 3: Ethyl (E)-3-[2-[(5-(phenylmethoxy)indolyl)methyl]-5-fluorophenyl]-2-propenoate

The benzylic bromide of Step 2 (3.16 g; 11.0 mmol) was coupled with 5-(phenylmethoxy)indole according to the same procedure described in step 1 of example 2 to yield 2.27 g of the title compound.

10 ^1H NMR (acetone- d_6) δ 1.27 (3H, t), 4.20 (2H, q), 5.11 (2H, s), 5.59 (2H, s), 6.43 (1H, dd), 6.52 (1H, d), 6.80 (1H, dd), 6.86 (1H, dd), 7.08 (1H, td), 7.19 (1H, d), 7.22 (1H, d), 7.31 (2H, m), 7.38 (2H, m), 7.50 (2H, m), 7.55 (1H, dd) and 8.01 (1H, dd).

15 Step 4: (E)-3-[2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl]-2-propenoic acid (493)

The hydrolysis of the ester of Step 3 (2.27 g) was done according to step 4 of example 1 to yield 2.07 g of the title compound.

20 ^1H NMR (acetone- d_6) δ 5.11 (2H, s), 5.62 (2H, s), 6.43 (1H, dd), 6.53 (1H, d), 6.75 (1H, dd), 6.86 (1H, dd), 7.08 (1H, td), , 7.19 (1H, d), 7.25 (1H, d), 7.31 (2H, m), 7.38 (2H, m), 7.50 (2H, m), 7.56 (1H, dd) and 8.04 (1H, dd). Elemental analysis calcd. for $\text{C}_{25}\text{H}_{20}\text{FNO}_3 \cdot 2\text{H}_2\text{O}$: C, 68.64; H, 5.53; N, 3.20; Found: C, 68.16; H, 4.95; N, 3.06.

25 Step 5: (E)-3-[2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl]-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-2-propenamide

The acid of Step 5 (2.06; 5.13 mmol) was coupled with 5-bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 2.44 g of the title compound.

30 ^1H NMR (acetone- d_6) δ 3.93 (3H, s), 5.10 (2H, s), 5.59 (2H, s), 6.39 (1H, dd), 6.73 (1H, dd), 6.78 (1H, d), 6.81 (1H, dd), 7.09 (1H, td), , 7.18 (1H, d), 7.24 (3H, m), 7.32 (1H, m), 7.39 (3H, m), 7.49 (2H, m), 7.82 (1H, dd), 8.01 (1H, dd) and 8.09 (1H, d). Elemental analysis calcd. for $\text{C}_{32}\text{H}_{26}\text{BrFN}_2\text{O}_5\text{S}_2$: C, 59.17; H, 4.03; N, 4.31; S, 4.94; Found: C, 59.07; H, 4.01; N, 4.34; S, 5.16.

35

EXAMPLE 26

5 (E)-3-[2-(BENZO[B]THIOPHEN-2-YLMETHYL)-5-FLUOROPHENYL]-N-
[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-2-PROPENAMIDE
SODIUM SALT (452)

10 Step 1: Ethyl (E)-3-[2-(benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-2-
propenoate

The ester (901 mg, 3.14 mmol) of example 13, step 2 was coupled with benzo[b]thiophene-2-boronic acid (from Lancaster Chemical) in DME according to the same procedure described in step 3 of example 10 to yield 657 mg of the title compound.

15 ^1H NMR (acetone- d_6) δ 1.22 (3H, t), 4.16 (2H, q), 4.43 (2H, s), 6.50 (1H, d), 7.03 (1H, s), 7.15-7.35 (3H, m), 7.47 (1H, dd), 7.56 (1H, dd), 7.69 (1H, dd), 7.78 (1H, dd) and 8.00 (1H, dd).

20 Step 2: (E)-3-[2-(benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-2-
propenoic acid (539)

The hydrolysis of the ester of Step 1 (657 mg) was done according to step 4 of example 1 to yield 345 mg of the title compound.

25 ^1H NMR (acetone- d_6) δ 4.45 (2H, s), 6.51 (1H, d), 7.04 (1H, d), 7.2-7.3 (3H, m), 7.49 (1H, dd), 7.57 (1H, dd), 7.70 (1H, d), 7.80 (1H, m) and 8.01 (1H, dd). Elemental analysis calcd. for $\text{C}_{18}\text{H}_{13}\text{FO}_2\text{S}$: C, 69.21; H, 4.19; Found: C, 68.96; H, 4.15.

Step 3: (E)-3-[2-(Benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-N-[(5-
bromo-2-methoxyphenyl)sulfonyl]-2-propenamide

30 The previous acid (264 mg; 0.85 mmol) was coupled with 5-bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 287 mg of the title compound.

35 ^1H NMR (acetone- d_6) δ 3.83 (3H, s), 4.43 (2H, s), 6.77 (1H, d), 7.00 (1H, d), 7.13 (1H, d), 7.2-7.3 (3H, m), 7.41 (1H, dd), 7.49 (1H, dd), 7.65 (1H, dd), 7.78 (2H, m), 7.96 (1H, dd) and 8.05 (1H, d).

The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for $\text{C}_{25}\text{H}_{18}\text{BrFNNaO}_4\text{S}_2\cdot\text{H}_2\text{O}$: C, 50.01; H, 3.36; N, 2.33; Found: C, 49.84; H, 3.22; N, 2.41.

5

EXAMPLE 27

N-(E)-[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-3-(5-FLUORO-2-
[[1-BENZYLINDOL-5-YL]METHYL]PHENYL)-2-PROPENAMIDE
SODIUM SALT (453)

10 Step 1: Ethyl (E)-3-[5-fluoro-2-(indol-5-ylmethyl)phenyl]-2-propenoate

The ester (1.83 g, 6.37 mmol) of example 13, step 2 was coupled with 5-indolyl boronic acid and NaHCO₃ in DME according to the procedure described in step 3 of example 10 to yield 1.08 g of the title compound.

15 ¹H NMR (acetone-d₆) δ 1.26 (3H, t), 4.17 (2H, q), 4.21 (2H, s), 6.37 (1H, m), 6.44 (1H, d), 6.94 (1H, dd), 7.14 (1H, td), 7.27-7.37 (4H, m), 7.51 (1H, dd), 8.05 (1H, dd) and 10.13 (1H, s).

20 Step 2: Ethyl (E)-3-(5-fluoro-2-[[1-benzylindol-5-yl]methyl]phenyl)-2-propenoate

The indole of Step 1 (621 mg; 1.92 mmol) was coupled with benzyl bromide according to the procedure described in step 1 of example 2 to yield 678 mg of the title compound.

25 ¹H NMR (acetone-d₆) δ 1.26 (3H, t), 4.17 (4H, m), 5.32 (2H, s), 6.43 (2H, m), 6.95 (1H, dd), 7.1-7.4 (11H, m), 7.49 (1H, dd) and 8.08 (1H, dd).

Step 3: (E)-3-(5-Fluoro-2-[[1-benzylindol-5-yl]methyl]phenyl)-2-propenoic acid) (540)

30 The hydrolysis of the ester of Step 2 (678 mg) was done according to step 4 of example 1 to yield 276 mg of the title compound.

¹H NMR (acetone-d₆) δ 4.20 (2H, s), 5.38 (2H, s), 6.39 (1H, d), 6.45 (1H, d), 6.95 (1H, d), 7.1-7.3 (10H, m), 7.48 (1H, d) and 8.04 (1H, dd).
Elemental analysis calcd. for C₂₅H₂₀FNO₂: C, 77.91; H, 5.23; N, 3.63;
35 Found: C, 78.52; H, 5.46; N, 3.66.

Step 4: N-(E)-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-(5-fluoro-2-[[1-benzylindol-5-yl]methyl]phenyl)-2-propenamide

5 The acid of Step 3 (219 mg; 0.57 mmol) was coupled with 5-bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 149 mg of the title compound.

¹H NMR (acetone-d₆) δ 3.82 (3H, s), 4.18 (2H, s), 5.38 (2H, s), 6.36 (1H, dd), 6.72 (1H, d), 6.90 (1H, dd), 7.1-7.4 (12H, m), 7.78 (1H, dd),
10 7.98 (1H, dd) and 8.05 (1H, d).

 The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C₃₂H₂₅BrFN₂NaO₄S.1/2H₂O: C, 57.84; H, 3.94; N, 4.22; Found: C, 57.61; H, 3.86; N, 4.16.

5

EXAMPLE 28

N-(E)-[(2,4-DIMETHYL(1,3-THIAZOL-5-YL))SULFONYL]-3-{3-[(5-
CHLOROINDOLYL)METHYL](2-PYRIDYL)}-2-PROPENAMIDE (444)

Step 1: Ethyl (E)-3-(3-methyl-2-pyridyl)-2-propenoate

10 To a solution of 2-bromo-3-methylpyridine (10.36 g; 60.2 mmol) in 120 mL of THF at -100 °C was added dropwise a 1.6 M solution of n-BuLi (65.6 mmol). After 20 min of stirring at that temperature, 1-formylpiperidine (7.65 g) in 10 mL of THF was added and the solution was warmed to r.t.. After 30 min of stirring at r.t., triethyl
15 phosphonoacetate (13.7 mL; 69.1 mmol) was added dropwise below 30 °C. After 1 h of stirring, the mixture was quenched with NH₄OAc (25%) and extracted with EtOAc. The solvent was removed and the crude oil was purified by silica gel chromatography (25% EtOAc in hexane) to yield
20 10.32 g of the title compound.

¹H NMR (acetone-d₆) δ 1.29 (3H, t), 2.46 (3H, s), 4.22 (2H, q), 6.99 (1H, d), 7.27 (1H, dd), 7.64 (1H, dt), 7.90 (1H, d) and 8.45 (1H, m).

Step 2: Ethyl (E)-3-[3-(bromomethyl)-2-pyridyl]-2-propenoate

The ester of Step 1 (5.93 g; 31.0 mmol) was converted in
25 benzene to the benzylic bromide according to the procedure described in step 2 of example 1 to yield 1.83 g of the title compound.

¹H NMR (acetone-d₆) δ 1.30 (3H, t), 4.25 (2H, q), 4.88 (2H, s), 7.10 (1H, d), 7.41 (1H, dd), 7.91 (1H, dd), 8.03 (1H, d) and 8.60 (1H, dd).

30 Step 3: Ethyl (E)-3-{3-[(5-chloroindolyl)methyl]-2-pyridyl}-2-propenoate

The benzylic bromide of Step 2 (1.33 g; 4.91 mmol) was coupled with 5-chloroindole according to the procedure described in step 1 of example 2 to yield 1.22 g of the title compound.

¹H NMR (acetone-d₆) δ 1.28 (3H, t), 4.22 (2H, q), 5.78 (2H, s),
35 6.57 (1H, d), 6.94 (1H, d), 7.04 (1H, d), 7.11 (1H, dd), 7.27 (1H, dd), 7.43 (2H, m), 7.63 (1H, d), 7.99 (1H, d) and 8.53 (1H, d).

Step 4: (E)-3-[3-[(5-Chloroindolyl)methyl]-2-pyridyl]-2-propenoic acid (542)

5 The hydrolysis of the ester of Step 3 (283 mg) was done according to step 4 of example 1 to yield 291 mg of the title compound.

¹H NMR (acetone-d₆) δ 5.81 (2H, s), 6.57 (1H, d), 6.88 (1H, d), 7.05 (1H, d), 7.11 (1H, dd), 7.26 (1H, dd), 7.43 (2H, m), 7.63 (1H, d), 8.02 (1H, d) and 8.54 (1H, d). Elemental analysis calcd. for
10 C₁₇H₁₃ClN₂O₂·1/4H₂O: C, 64.36; H, 4.29; N, 8.83; Found: C, 64.63; H, 4.43; N, 8.65.

Step 5: N-(E)-[(2,4-Dimethyl(1,3-thiazol-5-yl)sulfonyl]-3-[3-[(5-chloroindolyl)methyl](2-pyridyl)]-2-propenamide

15 The acid of Step 4 (283 mg; 0.90 mmol) was coupled with 2,4-dimethyl-1,3-thiazole-5-sulfonamide (from Maybridge Chemical) according to step 5 of example 1 to yield 315 mg of the title compound.

¹H NMR (acetone-d₆) δ 2.64 (3H, s), 2.69 (3H, s), 5.81 (2H, s), 6.56 (1H, d), 6.84 (1H, d), 7.09 (1H, dd), 7.26 (1H, dd), 7.31 (1H, d), 7.41 (2H, m), 7.62 (1H, d), 8.05 (1H, d) and 8.51 (1H, d). Elemental analysis calcd.
20 for C₂₂H₁₉ClN₄O₃S₂: C, 54.26; H, 3.93; N, 11.50; S, 13.17; Found: C, 54.69; H, 4.03; N, 11.18; S, 12.89.

EXAMPLE 29

25 N-[(E)-3-[5-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL-2-METHOXYBENZENESULFONAMIDE (302)]

The coupling reaction of the acid (3.00 g; 9.1 mmol) of Step 5 in Example 12 was done with 5-bromo-2-methoxybenzesulfonamide (2.56g; 9.6 mmol) according to Step 5 of Example 1 to yield 4.13g (79 %) of
30 the title compound. The sodium salt was prepared with 1N NaOH.

¹H NMR (DMSO-d₆) δ 3.76 (3H, s), 4.25 (2H, s), 6.52 (1H, d), 7.15 (1H, d), 7.26 (1H, d), 7.36 (1H, d), 7.41-7.52 (4H, m), 7.58 (1H, s), 7.69 (1H, m), 7.78 (1H, d), 7.82 (3H, m), 7.89 (1H, d) and 12.38 (1H, br s).

35

Elemental analysis:


Calcd. for C₂₇H₂₀BrClNNaO₄S·H₂O: C, 53.08; H, 3.64; N, 2.29;

Found: C, 53.25; H, 3.89; N, 2.91.

- 5 These intermediates were prepared according to the
literature:
5-fluoro-2-methylbenzaldehyde:
 Servis, K. L.; Fang, K.-N. *J. Am. Chem. Soc.* **1968**, 90, 6712-
6717.
- 10 5-indolyl boronic acid:
 Yang, Y.; Martin, A. R. *Heterocycles* **1992**, 34, 1395-1398.

5 WHAT IS CLAIMED IS:

1. A compound represented by formula I:



I

- 10 or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein:

HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

- 15 A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-, -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂- or -CR⁷=CR⁷-, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;

- 20 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;

Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸-;

B represents -(C(R¹⁸)₂)_p-Y-(C(R¹⁸)₂)_q-

- 25 wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸=CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

- 30 R¹, R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, - (C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, - CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;


each R⁴ is independently H, F, CF₃ or lower alkyl,

- 5 or two R^4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, $S(O)_n$ or $N(O)_m$;
- each R^5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , lower alkyl-HET, lower alkenyl-HET or $-(C(R^{18})_2)_pPh(R^{11})O-$
- 10 2;
- each R^6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF_3 , Ph, Bn and when two R^6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, $S(O)_n$ or
- 15 $N(O)_m$;
- each R^7 is independently H, F, CF_3 or lower alkyl, and when two R^7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, $S(O)_n$ and $N(O)_m$;
- 20 each R^8 represents H or R^5 ;
- each R^9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;
- each R^{10} is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , $Ph(R^{11})O-3$, $CH_2Ph(R^{11})O-3$ or $N(R^6)_2$;
- 25 each R^{11} is independently lower alkyl, SR^{20} , OR^{20} , $N(R^6)_2$, $-CO_2R^{12}$, $-CON(R^6)_2$, $-C(O)R^{12}$, CN, CF_3 , NO_2 or halogen;
- each R^{12} is independently H, lower alkyl or benzyl;
- each R^{13} is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, $N(R^6)_2$, CO_2R^{12} , CN, CF_3 or NO_2 ;
- 30 R^{14} and R^{15} are independently lower alkyl, halogen, CF_3 , OR^{16} , $S(O)_nR^{16}$ or $C(R^{16})_2OR^{17}$;
- each R^{16} is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF_3 ;
- each R^{17} is independently H, lower alkyl or Bn;
- 35 each R^{18} is independently H, F or lower alkyl, and when two R^{18} groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, $S(O)_n$ or N;

- 5 each R^{19} is lower alkyl, lower alkenyl, lower alkynyl, CF_3 ,
 HET(Ra)₄₋₉, lower alkyl-HET(Ra)₄₋₉ or lower alkenyl-HET(Ra)₄₋₉;
 each R^{20} is independently H, lower alkyl, lower alkenyl,
 lower alkynyl, CF_3 or $Ph(R^{13})_2$
 and
 10 each Ra is independently selected from the group consisting
 of:
 H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,
 C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino, di-C₁₋₆
 alkylamino, CF_3 , C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl,
 15 CO₂H, CO₂C₁₋₆alkyl,
 CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl, said alkyl, alkenyl, alkynyl and
 the alkyl portions of alkylamino and dialkylamino being optionally
 substituted with 1-3 of: hydroxy, halo, aryl, C₁₋₆ alkoxy, C₂₋₆alkenyloxy,
 C₂₋₆alkynyloxy, CF_3 , C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl,
 20 CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆
 alkyl and N(C₁₋₆alkyl)₂.

2. A compound represented by formula I:

25



I

or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein:

- HET represents a 5-12 membered monocyclic or bicyclic
 aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n
 30 and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

- A is a one or two atom moiety and is selected from the group
 consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-,
 -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂- or -CR⁷=CR⁷-, wherein
 W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as
 35 defined below;

- 5 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;
- Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸ = CR¹⁸- ;
- 10 B represents - (C(R¹⁸)₂)_p-Y- (C(R¹⁸)₂)_q-
- wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸ = CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;
- Z is OH or NHSO₂R¹⁹ ;
- 15 R¹ R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, -(C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;
- 20 each R⁴ is independently H, F, CF₃ or lower alkyl, or two R⁴ groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(O)_n or N(O)_m;
- each R⁵ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, lower alkyl-HET, lower alkenyl-HET or -(C(R¹⁸)₂)_pPh(R¹¹)₀₋₂;
- 25 each R⁶ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph, Bn and when two R⁶ groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(O)_n or N(O)_m;
- 30 each R⁷ is independently H, F, CF₃ or lower alkyl, and when two R⁷ groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(O)_n and N(O)_m;
- 35 each R⁸ represents H or R⁵;
- each R⁹ is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;

- 5 each R¹⁰ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph(R¹¹)₀₋₃, CH₂Ph(R¹¹)₀₋₃ or N(R⁶)₂ ;
 each R¹¹ is independently lower alkyl, SR²⁰, OR²⁰, N(R⁶)₂,
 -CO₂R¹², -CON(R⁶)₂, -C(O)R¹², CN, CF₃, NO₂ or halogen;
 each R¹² is independently H, lower alkyl or benzyl;
- 10 each R¹³ is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R⁶)₂, CO₂R¹², CN, CF₃ or NO₂ ;
 R¹⁴ and R¹⁵ are independently lower alkyl, halogen, CF₃, OR¹⁶, S(O)_nR¹⁶ or C(R¹⁶)₂OR¹⁷ ;
 each R¹⁶ is independently H, lower alkyl, lower alkenyl, Ph,
- 15 Bn, CHF₂ or CF₃;
 each R¹⁷ is independently H, lower alkyl or Bn;
 each R¹⁸ is independently H, F or lower alkyl, and when two R¹⁸ groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one
- 20 heteroatom chosen from O, S(O)_n or N;
 each R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl, CF₃, HET²(Ra)₄₋₉, lower alkyl-HET²(Ra)₄₋₉ or lower alkenyl-HET²(Ra)₄₋₉, wherein HET² represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl;
- 25 each R²⁰ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CHF₂, CF₃ or Ph(R¹³)₂
 and
 each Ra is independently selected from the group consisting of:
- 30 H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino, di-C₁₋₆alkylamino, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl,
 said alkyl, alkenyl, alkynyl and the alkyl portions of
- 35 alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆alkyl and N(C₁₋₆alkyl)₂.

5

3. A compound in accordance with claim 1 wherein:
HET represents a member selected from the group
consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline,
isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole,
10 thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole,
thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,3-
methylenedioxobenzene and pyrrole.

15

4. A compound in accordance with claim 3 wherein:
HET is selected from the group consisting of: phenyl,
biphenyl, naphthyl, indole, thiophene, benzofuran and quinoline.

20

5. A compound in accordance with claim 1 wherein:
A represents a one or two atom moiety and is selected from
the group consisting of: S, S(O), SO₂, CH₂, -C(O)-, -OCH₂-, -CHOH-,
-C(OH)(CH₃)- and -CH₂O-.

25

6. A compound in accordance with claim 5 wherein:
A is selected from the group consisting of: S, S(O), SO₂,
CH₂ and -C(O)-.

30

7. A compound in accordance with claim 1 wherein:
X represents phenyl optionally substituted with R¹⁴ and R¹⁵.

8. A compound in accordance with claim 7 wherein X
represents phenyl and R¹⁴ and R¹⁵ are absent or represent halo.

35

9. A compound in accordance with claim 1 wherein:
B represents CH=CH or 1,2-cyclopropyl.

10. A compound in accordance with claim 9 wherein:
B represents CH=CH in the E-isomeric form.

- 5 11. A compound in accordance with claim 9 wherein:
Z is $\text{NHSO}_2\text{R}^{19}$.
12. A compound in accordance with claim 11 wherein:
Z is $\text{NHSO}_2\text{R}^{19}$ and R^{19} represents a member selected from
10 the group consisting of: lower alkyl and $\text{HET}(\text{Ra})_3$.
13. A compound in accordance with claim 12 wherein:
R¹⁹ represents $\text{HET}(\text{Ra})_3$ and HET is selected from the
group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl,
15 imidazolyl and indolyl.
14. A compound in accordance with claim 12 wherein:
Z is $\text{NHSO}_2\text{R}^{19}$ and R^{19} represents benzene or thiophene,
substituted with $(\text{Ra})_3$.
20
15. A compound in accordance with claim 1 wherein:
Z represents OH.
16. A compound in accordance with claim 1 wherein:
25 HET represents a member selected from the group
consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline,
isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole,
thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine,
indole, tetrazole, imidazole, benzoxazole and pyrrole;
30 A represents a one or two atom moiety and is selected from
the group consisting of: S, S(O), SO₂, CH₂, -C(O)-, -OCH₂-, -CHOH-, -
C(OH)(CH₃)- and -CH₂-O-;
X represents phenyl optionally substituted with R¹⁴ and R¹⁵;
B is CH=CH;
35 Z is $\text{NHSO}_2\text{R}^{19}$ and
R¹⁹ represents a member selected from the group consisting
of: lower alkyl and $\text{HET}(\text{Ra})_3$.

5 17. A compound in accordance with claim 1 wherein:

HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine,
 10 indole, tetrazole, imidazole, benzoxazole and pyrrole;

A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO₂, CH₂, -C(O)-, -OCH₂-, -CHOH-, -C(OH)(CH₃)- and -CH₂-O-;


X represents phenyl optionally substituted with R¹⁴ and R¹⁵;

15 B is CH=CH;

Z is OH.

18. A compound represented in one of the following tables:

20



| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-------------------|--------|-------|--------------------|-----|
| 1-naphthyl | CH ₂ | 1,2-Ph | CH=CH | Ph(F) ₅ | 1 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | Ph(F) ₅ | 2 |
| 3-methylindol -1-yl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 3 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 4 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | phenyl | 5 |
| 3-methylindol -1-yl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 6 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-------------------|--------|----------------------------------|----------------------------------|-----|
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 7 |
| 3,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 8 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 9 |
| 2,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 10 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | Ph(F) ₅ | 11 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 12 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 13 |
| 3,4-chloro fluoro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 14 |
| 1-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 15 |
| 3,4-dichloro phenyl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 16 |
| 4-methylthio phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 17 |
| 4-chlorophenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 18 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 2-thienyl | 19 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 20 |
| 2-naphthyl | S(O) | 1,2-Ph | CH=CH | 2-thienyl | 21 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | phenyl | 22 |
| 2-benzofuranyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 23 |
| 3,5-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 24 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 25 |
| 1-naphthyl | S(O) ₂ | 1,2-Ph | CH=CH | 2-thienyl | 26 |
| 3-(1,2-(methylene dioxy)benzene) | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 27 |
| 2-naphthyl | O | 1,2-Ph | CH=CH | 2-thienyl | 28 |
| Rs-2-phenyl | CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 29 |
| Rs-2-phenyl | CH ₂ | 1,2-Ph | CH ₂ -CH ₂ | 2-thienyl | 30 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 31 |
| 3-((2-(Qn)vinyl)) phenyl | CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 32 |
| 2-(6-benzyloxy) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 33 |
| 3-((2-(Qn)vinyl)) phenyl | SO | 1,2-Ph | CH ₂ -O | 2-thienyl | 34 |
| 3-((2-(Qn)vinyl)) phenyl | -CHOH | 1,2-Ph | CH ₂ -O | 2-thienyl | 35 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|------------------------------|--------|-------------------------------------|-----------------------------|-----|
| 3-((2-(Qn)vinyl)) phenyl | S(O) ₂ | 1,2-Ph | CH ₂ -O | phenyl | 36 |
| 3-((2-(Qn)vinyl)) phenyl | O-CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 37 |
| 3-tolyl-D-3-phenyl | O-CH ₂ | 1,2-Ph | CH ₂ -O | 2-thienyl | 38 |
| 3-((2-(Qn)vinyl)) phenyl | CH(OH)- CH ₃ - | 1,2-Ph | CH ₂ -O | phenyl | 39 |
| 3-((2-(Qn)vinyl)) phenyl | S | 1,2-Ph | CH ₂ -O | 2-thienyl | 40 |
| 3-((2-(Qn)vinyl)) phenyl | O | 1,2-Ph | CH ₂ -O | phenyl | 41 |
| 3-((2-(Qn)vinyl)) phenyl | C=O | 1,2-Ph | CH ₂ -O | 2-thienyl | 42 |
| 3-((2-(Qn)vinyl)) phenyl | O | 1,2-Ph | C(CH ₃) ₂ -O | 2-thienyl | 43 |
| 3-((2-(Qn)vinyl)) phenyl | O | 1,2-Ph | CH ₂ -O | 2-thienyl | 44 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 45 |
| 2-(6-benzyloxy) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5- bromophenyl | 46 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichloro phenyl | 47 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluoro phenyl | 48 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-chloro phenyl | 49 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-propyl phenyl | 50 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro thienyl | 51 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | styryl | 52 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4- fluorophenyl | 53 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxy phenyl | 54 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromo phenyl | 55 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethyl phenyl | 56 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chloro phenyl | 57 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxy phenyl | 58 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|---|-----|
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluoro phenyl | 59 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-butyl-phenyl | 60 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | butyl | 61 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxy phenyl | 62 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoro methylphenyl | 63 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluoro phenyl | 64 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichloro phenyl | 65 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1-methyl)ethyl) phenyl | 66 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxy methyl)phenyl | 67 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxy methyl)phenyl | 68 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methyl sulfonyl)phenyl | 69 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methyl sulfonyl)phenyl | 70 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propyl sulfonyl)phenyl | 71 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoro-methyl)-hydroxy methyl)phenyl | 72 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy) phenyl | 73 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1-methyl) ethyl)phenyl | 74 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethyl aminophenyl | 75 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 76 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 77 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinYL | 78 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 79 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 80 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 81 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 82 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)- furanyl | 83 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-------------------|--------|--------------|---|-----|
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 84 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro)pyridinyl | 85 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 86 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 87 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 88 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1-methyl)ethyl)phenyl | 89 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxymethyl)phenyl | 90 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxymethyl)phenyl | 91 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethylphenyl | 92 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxyphenyl | 93 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluorophenyl | 94 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methylsulfonyl)phenyl | 95 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methylsulfonyl)phenyl | 96 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propylsulfonyl)phenyl | 97 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-butyl-phenyl | 98 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-di-(CF ₃)phenyl | 99 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoromethyl)-hydroxymethyl)phenyl | 100 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromophenyl | 101 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy)phenyl | 102 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chlorophenyl | 103 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-isopropylphenyl | 104 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1-methyl)ethyl)phenyl | 105 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxyphenyl | 106 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-------------------|--------|--------------|----------------------------------|-----|
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethyl aminophenyl | 107 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichloro phenyl | 108 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluoro phenyl | 109 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluorophenyl | 110 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 111 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 112 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinyl | 113 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | butyl | 114 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-chlorophenyl | 115 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-propylphenyl | 116 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 117 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 118 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 119 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxy phenyl | 120 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoro methylphenyl | 121 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro-3-thienyl | 122 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 123 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)-furanyl | 124 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 125 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-styryl | 126 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluoro-phenyl | 127 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichloro-phenyl | 128 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro) pyridinyl | 129 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 130 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 131 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 132 |
| 2-naphthyl | S(O) ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4-fluorophenyl | 133 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-di-(CF ₃)-phenyl | 134 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-isopropyl phenyl | 135 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichloro phenyl | 136 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁰ | Cpd |
|---|-----------------|--------|--------------|-------------------------------------|-----|
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluorophenyl | 137 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluorophenyl | 138 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-chlorophenyl | 139 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-propylphenyl | 140 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro-3-thienyl | 141 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-styryl | 142 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4-fluorophenyl | 143 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxyphenyl | 144 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromophenyl | 145 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethylphenyl | 146 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chlorophenyl | 147 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxyphenyl | 148 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluorophenyl | 149 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-butylphenyl | 150 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | n-butyl | 151 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxyphenyl | 152 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoromethylphenyl | 153 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluorophenyl | 154 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichlorophenyl | 155 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1-methyl)ethyl)phenyl | 156 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxymethyl)phenyl | 157 |

| R¹R²R³-Het | A | X | B | R¹⁹ | Cpd |
|--|-----------------|----------|--------------|--|------------|
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxymethyl)phenyl | 158 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methylsulfonyl)phenyl | 159 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methylsulfonyl)phenyl | 160 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propylsulfonyl)phenyl | 161 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoromethyl)hydroxymethyl)phenyl | 162 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy)phenyl | 163 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1-methyl)ethyl)phenyl | 164 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethylaminophenyl | 165 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 166 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 167 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinyl | 168 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 169 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 170 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 171 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 172 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)-furanyl | 173 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 174 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro)pyridinyl | 175 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 176 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 177 |
| 3-methylindol-1-yl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 178 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|----------------------------------|-----|
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-di-(CF ₃) phenyl | 179 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-isopropyl phenyl | 180 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-dichloro phenyl | 181 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluoro phenyl | 182 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-fluorophenyl | 183 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-chlorophenyl | 184 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-propylphenyl | 185 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dichloro-3-thienyl | 186 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-styryl | 187 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-chloro-4-fluorophenyl | 188 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-methoxy phenyl | 189 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-bromo phenyl | 190 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethyl phenyl | 191 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-nitro-4-chloro phenyl | 192 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-carbomethoxy phenyl | 193 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,4-difluoro phenyl | 194 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-butylphenyl | 195 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | n-butyl | 196 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2,5-dimethoxy phenyl | 197 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-trifluoromethyl phenyl | 198 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-difluoro phenyl | 199 |
| 1-(3-methyl) indolyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,5-dichloro phenyl | 200 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|--|-----|
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-hydroxy-1-methyl)ethyl)phenyl | 201 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(hydroxymethyl)phenyl | 202 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-(hydroxymethyl)phenyl | 203 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(methylsulfonyl)phenyl | 204 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-(methylsulfonyl)phenyl | 205 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(propylsulfonyl)phenyl | 206 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-((bis-trifluoromethyl)hydroxymethyl)phenyl | 207 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-(benzyloxy)phenyl | 208 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-((1-methoxy-1-methyl)ethyl)phenyl | 209 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-dimethylaminophenyl | 210 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | cyclohexyl | 211 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | cyclopentyl | 212 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-morpholinyl | 213 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-naphthyl | 214 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-thiazolyl | 215 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 1-imidazolyl | 216 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-furanyl | 217 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-(2-chloro)-furanyl | 218 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-pyridinyl | 219 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-(4-chloro)pyridinyl | 220 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|--------------------------------------|-----|
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3-indolyl | 221 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-nitrophenyl | 222 |
| 3-methylindol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 4-cyanophenyl | 223 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 224 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 225 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 226 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 227 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-chlorophenyl | 228 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-fluorophenyl | 229 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2,5-dichloro-3-thienyl | 230 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3-chloro-4-fluoro phenyl | 231 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-methoxy phenyl | 232 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | butyl | 233 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3-trifluoro methylphenyl | 234 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-((1-hydroxy-1-methyl)ethyl) phenyl | 235 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-(methyl sulfonyl)phenyl | 236 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-(benzyloxy) phenyl | 237 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | cyclohexyl | 238 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-morpholinyl | 239 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thiazolyl | 240 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-furanyl | 241 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-pyridinyl | 242 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 4-cyanophenyl | 243 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 244 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 245 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 246 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|--------------------|--------|-------|--------------------------------------|-----|
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 247 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-chlorophenyl | 248 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-fluorophenyl | 249 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2,5-dichloro-3-thienyl | 250 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3-chloro-4-fluorophenyl | 251 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-methoxy phenyl | 252 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | butyl | 253 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3-trifluoro methylphenyl | 254 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-((1-hydroxy-1-methyl)ethyl) phenyl | 255 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-(methyl sufonyl)phenyl | 256 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-(benzyloxy) phenyl | 257 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | cyclohexyl | 258 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-morpholinyl | 259 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thiazolyl | 260 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-furanyl | 261 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-pyridinyl | 262 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 4-cyanophenyl | 263 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 264 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 265 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 266 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 267 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 268 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 269 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 270 |
| 2-naphthyl | O-CH ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 271 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 272 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------|--------------|---------------------|-----|
| 2-naphthyl | S | 1,2-Ph | CH=CH | 4-isopropyl phenyl | 273 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 2,3-dichloro phenyl | 274 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 275 |
| 2-(6-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 276 |
| 2-(6-benzyloxy) naphthyl | S | 1,2-Ph | CH=CH | 2-thienyl | 277 |
| 2-(6-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 278 |
| 2-(6-benzyloxy) naphthyl | S | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 279 |
| 2-(5-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 280 |
| 2-(5-benzyloxy) naphthyl | S | 1,2-Ph | CH=CH | 2-thienyl | 281 |
| 2-(5-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 282 |
| 2-(5-benzyloxy) naphthyl | S | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 283 |
| 2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 284 |
| 2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 285 |
| 2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 286 |
| 2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 287 |
| 1-(6-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 288 |
| 1-(6-benzyloxy) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 289 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 290 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 291 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-------------|--------------|----------------------------------|-----|
| 2-(6-(4-fluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-thienyl | 292 |
| 2-(7-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-thienyl | 293 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 294 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,4-difluoro phenyl | 295 |
| 2-(6-(4-fluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluoro phenyl | 296 |
| 2-(7-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 297 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 298 |
| 2-(6-(3,4-difluoro benzyloxy)) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 3,5-di-(CF ₃) phenyl | 299 |
| 2-(7-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 3,4-difluoro phenyl | 300 |
| 2-naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 301 |
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 302 |
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 303 |
| 2-naphthyl | SO | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 304 |
| 2-naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 305 |
| 2-naphthyl | O | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 306 |
| 2-(5-benzyloxy) naphthyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 307 |
| 2-(5-benzyloxy) naphthyl | SO ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 308 |
| 2-(5-benzyloxy) naphthyl | S | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 309 |
| 2-naphthyl | CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 310 |
| 1,2-Ph | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 311 |

| R ¹ R ² R ³ .Het | A | X | B | R ¹⁹ | Cpd |
|---|--------------------|-------------|--------------|-------------------------|-----|
| 2-naphthyl | S | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 312 |
| 2-naphthyl | CH ₂ -O | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 313 |
| 2-naphthyl | S | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 314 |
| 3-methyl indol-1-yl | SO ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 315 |
| 3-methyl indol-1-yl | S | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 316 |
| 3-methyl indol-1-yl | CH ₂ -O | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 317 |
| 3-methyl indol-1-yl | S | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 318 |
| 3-methyl indol-1-yl | O-CH ₂ | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 319 |
| 3-methyl indol-1-yl | SO | 1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 320 |
| 3-methyl indol-1-yl | CH ₂ -O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 321 |
| 3-methyl indol-1-yl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 322 |
| 3-methyl indol-1-yl | SO ₂ | 4-Cl-1,2-Ph | 1,2-c-propyl | 2-methoxy-5-bromophenyl | 323 |
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 347 |
| 2-(7-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 348 |
| 2-(7-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 349 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 350 |
| 2-(7-fluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 351 |
| 2-(7-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 352 |
| 2-(7-fluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 353 |
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 354 |
| 2-(7-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 355 |
| 2-(7-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 356 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-----------------------------|----------|-----------------------------------|-----|
| 2-naphthyl | CH ₂ | 4,5-Cl ₂ -1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 357 |
| 2-(7-fluoro)naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 358 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 359 |
| 2-(7-fluoro)naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 360 |
| 2-(7-fluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-trifluoromethoxy-5-chlorophenyl | 361 |
| 2-(7-fluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-trifluoromethoxy-5-chlorophenyl | 362 |
| 2-(7-fluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-trifluoromethoxy-5-chlorophenyl | 363 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-trifluoromethoxy-5-chlorophenyl | 364 |
| 2-(7-fluoro)naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-trifluoromethoxy-5-chlorophenyl | 365 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-trifluoromethoxy-5-chlorophenyl | 366 |
| 2-(7-fluoro)naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-trifluoromethoxy-5-chlorophenyl | 367 |
| 2-(7-fluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 368 |
| 2-(7-fluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 369 |
| 2-(7-fluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 370 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 371 |
| 2-(7-fluoro)naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 372 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 373 |
| 2-(7-fluoro)naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 374 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-------------|----------|-------------------------|-----|
| 2-(7-fluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 375 |
| 2-(6-fluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 376 |
| 2-(6-fluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 377 |
| 2-(6-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 378 |
| 2-(6-fluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 379 |
| 2-(6-fluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 380 |
| 2-(6-fluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 381 |
| 2-(7-chloro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 382 |
| 2-(7-chloro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 383 |
| 2-(7-chloro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 384 |
| 2-(7-chloro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 385 |
| 2-(7-chloro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 386 |
| 2-(7-chloro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 387 |
| 2-(7-chloro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 388 |
| 2-(6,7-difluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 389 |
| 2-(6,7-difluoro) naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 390 |
| 2-(6,7-difluoro) naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 391 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 392 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-thienyl | 393 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-thienyl | 394 |
| 2-(6,7-difluoro) naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-thienyl | 395 |
| 2-(6,7-difluoro) naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 396 |


| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-------------|----------|-------------------------|-----|
| 2-(6,7-difluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 397 |
| 2-(6,7-difluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 398 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 399 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 6-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 400 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 401 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 3-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 402 |
| 2-(5,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 403 |
| 2-(5,7-difluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 404 |
| 2-(5,7-difluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 405 |
| 2-(5,7-difluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 406 |
| 2-(6-fluoro)quinoliny | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 407 |
| 2-(6-fluoro)quinoliny | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 408 |
| 2-(6-fluoro)quinoliny | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 409 |
| 2-(6-fluoro)quinoliny | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 410 |
| 2-(6-fluoro)quinoliny | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 411 |
| 2-(6-fluoro)quinoliny | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 412 |
| 2-(5,7-difluoro)-quinoliny | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 413 |
| 2-(5,7-difluoro)-quinoliny | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 414 |
| 2-(5,7-difluoro)-quinoliny | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 415 |
| 2-(5,7-difluoro)-quinoliny | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 416 |
| 2-(5,7-difluoro)-quinoliny | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 417 |
| 2-(5,7-difluoro)-quinoliny | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 418 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|-------------|----------|-------------------------|-----|
| 3,4-dichloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 419 |
| 3,4-dichloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 420 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 421 |
| 3,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 422 |
| 3,4-dichloro phenyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 423 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 424 |
| 3,4-dichloro phenyl | CH ₂ | 5-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 425 |
| 4-chloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 426 |
| 4-chloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 427 |
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 428 |
| 4-chloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 429 |
| 4-chloro phenyl | O | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 430 |
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 2-methoxy-5-bromophenyl | 431 |
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 432 |
| 3,4-dichloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 433 |
| 3,4-dichloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 434 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 435 |
| 3,4-dichloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 436 |
| 3,4-dichloro phenyl | O | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 437 |
| 3,4-dichloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 438 |
| 3,4-dichloro phenyl | CH ₂ | 5-Cl-1,2-Ph | CH=CH | 2-thienyl | 439 |
| 4-chloro phenyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 440 |

| R ¹ R ² R ³ -Het | A | X | B | R ¹⁹ | Cpd |
|---|-----------------|--------------|-------|-------------------------------------|-----|
| 4-chloro phenyl | S | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 441 |
| 4-chloro phenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-thienyl | 442 |
| 4-chloro phenyl | CH ₂ | 1,2-Ph | CH=CH | 2-thienyl | 443 |
| 1-(5-chloro) indolyl | CH ₂ | 3,2-Pyr | CH=CH | 2,4-(Me) ₂ -thiazol-5-yl | 444 |
| 1-(5-chloro) indolyl | CH ₂ | 3,2-Pyr | CH=CH | 2-thienyl | 445 |
| 1-(6-(4-chloro) phenyl)indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 3-chloro-4-fluorophenyl | 446 |
| 2-(6-difluoro methoxy) naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 447 |
| 2-naphthyl | CH ₂ | 4-MeO-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 448 |
| 2-naphthyl | CH ₂ | 5-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 449 |
| 2-(6-chloro naphthyl) | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 450 |
| 1-(5-phenyl methoxy) indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 451 |
| 2-(benzo[b] thiophenyl) | CH ₂ | 4-F-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 452 |
| 5-(1-benzyl) indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 453 |
| 1-(6-(4-chloro) phenyl)indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 2-methoxy-5-bromophenyl | 454 |

5

Table II



I-b

(Compounds 324-346 and 455-542)

5

| R ¹ R ² R ³ -Het | A | X | B | Cpd |
|---|--------------------|-------------|----------------------------------|-----|
| 2-naphthyl | S(O) ₂ | 1,2-phenyl | CH=CH | 324 |
| 2-naphthyl | S | 1,2-phenyl | CH=CH | 325 |
| 4-methylthiophenyl | CH ₂ | 1,2-phenyl | CH=CH | 326 |
| 3-methylindol-1-yl | CH ₂ | 1,2-phenyl | CH=CH | 327 |
| 3-chloro-4-fluorophenyl | CH ₂ | 1,2-phenyl | CH=CH | 328 |
| 4-chlorophenyl | CH ₂ | 1,2-phenyl | CH=CH | 329 |
| 2-naphthyl | CH ₂ | 1,2-phenyl | CH=CH | 330 |
| 2-naphthyl | S(O) ₂ | 1,2-phenyl | 1,2-c-propyl | 331 |
| 2-naphthyl | S(O) ₂ | 1,2-phenyl | CH ₂ -CH ₂ | 332 |
| 2-naphthyl | S | 1,2-phenyl | CH=CH | 333 |
| 3,4-dichlorophenyl | S(O) ₂ | 1,2-phenyl | CH ₂ -CH ₂ | 334 |
| 3,4-dichlorophenyl | CH ₂ | 1,2-phenyl | CH=CH | 335 |
| 2-(6-benzyloxy)naphthyl | CH ₂ | 1,2-phenyl | CH=CH | 336 |
| 2-(6-benzyloxy)naphthyl | CH ₂ | 1,2-phenyl | 1,2-c-propyl | 337 |
| 2-(6-benzyloxy)naphthyl | SO ₂ | 1,2-phenyl | 1,2-c-propyl | 338 |
| 2-(6-benzyloxy)naphthyl | CH ₂ -O | 1,2-phenyl | 1,2-c-propyl | 339 |
| 2-(6-benzyloxy)naphthyl | O-CH ₂ | 1,2-phenyl | 1,2-c-propyl | 340 |
| 2-(6-benzyloxy)naphthyl | SO ₂ | 1,2-phenyl | CH=CH | 341 |
| 2-(6-benzyloxy)naphthyl | CH ₂ -O | 1,2-phenyl | CH=CH | 342 |
| 2-(6-benzyloxy)naphthyl | O-CH ₂ | 1,2-phenyl | CH=CH | 343 |
| 2-(6-benzyloxy)naphthyl | S | 1,2-phenyl | CH=CH | 344 |
| 2-(7-benzyloxy)naphthyl | SO ₂ | 1,2-phenyl | CH=CH | 345 |
| 2-(6-(4-trifluoromethyl)benzyloxy)naphthyl | CH ₂ | 1,2-phenyl | CH=CH | 346 |
| 2-(6-fluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 455 |
| 2-(6-fluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 456 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 457 |
| 2-(6-fluoro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 458 |
| 2-(6-fluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 459 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 460 |
| 2-(7-fluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 461 |
| 2-(7-fluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 462 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 463 |
| 2-(7-fluoro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 464 |
| 2-(7-fluoro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 465 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 466 |
| 2-(6-chloro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 467 |
| 2-(6-chloro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 468 |
| 2-(6-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 469 |
| 2-(6-chloro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 470 |
| 2-(6-chloro)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 471 |

| R ¹ R ² R ³ -Het | A | X | B | Cpd |
|---|-----------------|-------------|----------|-----|
| 2-(6-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 472 |
| 2-(7-chloro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 473 |
| 2-(7-chloro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 474 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 475 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 476 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 477 |
| 2-(7-chloro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 478 |
| 2-(6,7-difluoro)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 479 |
| 2-(6,7-difluoro)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 480 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 481 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 482 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 483 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 484 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 485 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 486 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 487 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 1,2-Ph | CH=CH | 488 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 489 |
| 2-(6,7-difluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | 1,2-c-Pr | 490 |
| 3-methyl-5-fluoro indol-1-yl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 491 |
| 3-methyl-5-fluoro indol-1-yl | S | 4-Cl-1,2-Ph | CH=CH | 492 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 493 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 1,2-Ph | CH=CH | 494 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 495 |
| 3-methyl-5-fluoro indol-1-yl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 496 |
| 2-(6-fluoro)quinolinyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 497 |
| 2-(6-fluoro)quinolinyl | S | 4-Cl-1,2-Ph | CH=CH | 498 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 499 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 500 |
| 2-(6-fluoro)quinolinyl | O | 4-Cl-1,2-Ph | CH=CH | 501 |
| 2-(6-fluoro)quinolinyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 502 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 503 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 504 |
| 2-(6-difluoromethoxy)- naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 505 |

| R ¹ R ² R ³ -Het | A | X | B | Cpd |
|---|-----------------|-----------------------------|-------|-----|
| 2-(6-difluoromethoxy)-naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 506 |
| 2-(6-difluoromethoxy)-naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 507 |
| 2-(6-difluoromethoxy)-naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 508 |
| 2-(7-difluoromethoxy)-naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 509 |
| 2-(7-difluoromethoxy)-naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 510 |
| 2-(7-difluoromethoxy)-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 511 |
| 2-(7-difluoromethoxy)-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 512 |
| 2-(7-difluoromethoxy)-aphthyl | O | 4-Cl-1,2-Ph | CH=CH | 513 |
| 2-(7-difluoromethoxy)-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 514 |
| 2-(6-methoxy)naphthyl | SO ₂ | 4-Cl-1,2-Ph | CH=CH | 515 |
| 2-(6-methoxy)naphthyl | S | 4-Cl-1,2-Ph | CH=CH | 516 |
| 2-(6-methoxy)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 517 |
| 2-(6-methoxy)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 518 |
| 2-(6-methoxy)naphthyl | O | 4-Cl-1,2-Ph | CH=CH | 519 |
| 2-(6-methoxy)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 520 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 521 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 522 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 523 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 524 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 525 |
| 2-(6-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 526 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 527 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 528 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 529 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 530 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 531 |
| 2-(7-fluoro)naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 532 |
| 2-naphthyl | CH ₂ | 4,5-Cl ₂ -1,2-Ph | CH=CH | 533 |
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 534 |
| 3,4-dichlorophenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 535 |
| 2-naphthyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 536 |
| 4-chlorophenyl | CH ₂ | 4-Cl-1,2-Ph | CH=CH | 537 |
| 1-(5-phenylmethoxy)indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 538 |

| R ¹ R ² R ³ -Het | A | X | B | Cpd |
|---|-----------------|------------|-------|-----|
| 2-(benzo[b]thiophenyl) | CH ₂ | 4-F-1,2-Ph | CH=CH | 539 |
| 5-(1-benzyl)indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 540 |
| 1-(6-(4-chloro)phenyl) indolyl | CH ₂ | 4-F-1,2-Ph | CH=CH | 541 |
| 1-(5-chloro)indolyl | CH ₂ | 3,2-Pyr | CH=CH | 542 |

5

wherein D = -O(CH₂)₃-O, Qn = 7-chloroquinolin-2-yl, 1,2-Ph = 1,2-benzenediyl, Rs = -CH₂SCH₂CH₂Ph, Pyr = pyridinediyl, c-pr = cyclopropyl and Bn = benzyl.

19. A pharmaceutical composition which is
 10 comprised of a compound in accordance with any one of claims 1 to 18 in combination with a pharmaceutically acceptable carrier.

20. A method of treating or preventing a prostaglandin mediated disease which is comprised of administering to a mammalian
 15 patient in need of such treatment a compound in accordance with claim 1 in an amount which is effective for treating or preventing a prostaglandin mediated disease.

21. A method in accordance with claim 19 wherein the
 20 prostaglandin mediated disease is selected from the group consisting of:
 pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia,
 25 synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures, immune and autoimmune diseases;
 30 cellular neoplastic transformations or metastatic tumor growth;
 diabetic retinopathy, tumor angiogenesis;

- 5 prostanoid-induced smooth muscle contraction associated
with dysmenorrhea, premature labor, asthma or eosinophil related
disorders;
- Alzheimer's disease;
 glaucoma;
10 bone loss;
 osteoporosis;
 promotion of bone formation;
 Paget's disease;
 cytoprotection in peptic ulcers, gastritis, regional enteritis,
15 ulcerative colitis, diverticulitis or other gastrointestinal lesions; GI
bleeding and patients undergoing chemotherapy;
 coagulation disorders selected from hypoprothrombinemia,
haemophilia and other bleeding problems;
 kidney disease;
20 thrombosis;
 occlusive vascular disease;
 presurgery;
 and anti-coagulation.
- 25 22. A method in accordance with claim 20 wherein the
prostaglandin mediated disease is selected from the group consisting of:
pain, fever or inflammation.
23. A method in accordance with claim 20 wherein the
30 prostaglandin mediated disease is dysmenorrhea.
24. A method in accordance with claim 20, wherein the
compound is co-administered with other agents or ingredients.
- 35 25. A method in accordance with claim 24 wherein the
compound I is co-administered with another agent or ingredient
selected from the group consisting of: an analgesic selected from
acetaminophen, phenacetin, aspirin, a narcotic;

- 5 a COX-2 selective NSAID and a conventional NSAID;
caffeine;
an H₂-antagonist;
aluminum or magnesium hydroxide;
simethicone;
- 10 a decongestant selected from phenylephrine,
phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine,
naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine;
an antiitussive selected from codeine, hydrocodone,
caramiphen, carbetapentane and dexamethorphan;
- 15 another prostaglandin ligand selected from misoprostol,
enprostil, rioprostil, ornoprostol and rosaprostol; a diuretic; and
a sedating or non-sedating antihistamine.
26. Use of a compound, salt, hydrate or ester as
defined in any one of claims 1 to 18 in the manufacture of a
- 20 medicament for treatment or prevention of a prostaglandin
mediated disease.
27. A compound, salt, hydrate or ester as defined in
any one of claims 1 to 18 for use in the treatment or prevention of
a prostaglandin mediated disease.
- 25 28. A prostaglandin antagonist pharmaceutical
composition comprising an acceptable prostaglandin antagonistic
amount of a compound, salt, hydrate or ester as defined in any one
of claims 1 to 18, in association with a pharmaceutically
acceptable carrier.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁶ : C07C 57/42, 59/68, 59/84, 311/51, C07D 209/10, 307/64, 307/79 | A3 | (11) International Publication Number: WO 99/47497 (43) International Publication Date: 23 September 1999 (23.09.99) |
| (21) International Application Number: PCT/CA99/00212 (22) International Filing Date: 12 March 1999 (12.03.99) (30) Priority Data: 60/077,990 13 March 1998 (13.03.98) US 9815856.1 21 July 1998 (21.07.98) GB (71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): GAREAU, Yves [CA/CA]; (CA). LABELLE, Marc [CA/CA]; (CA). JUTEAU, Helene [CA/CA]; (CA). GALLANT, Michel [CA/CA]; (CA). LACHANCE, Nicolas [CA/CA]; (CA). BELLEY, Michel [CA/CA]; 16711 Trans-Canada High- way, Kirkland, Quebec H9H 3L1 (CA). (74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA). | | (81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 28 October 1999 (28.10.99) |
| (54) Title: CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT <div style="text-align: center; margin: 20px 0;"> $\begin{array}{c} R^1 R^2 R^3 - HET \\ \quad \quad \quad \diagdown \\ \quad \quad \quad A \\ \quad \quad \quad \\ X - B \quad \quad \quad \diagup \quad \quad \quad \diagdown \\ \quad \quad \quad \quad \quad \quad \quad \quad \quad \quad O \\ \quad \quad \quad \quad \quad \quad \quad \quad \quad \quad \\ \quad \quad \quad \quad \quad \quad \quad \quad \quad \quad Z \end{array} \tag{I}$ </div> (57) Abstract <p>Compounds of formula (I), as well as pharmaceutically acceptable salts, hydrates and esters thereof, are disclosed. The compounds are useful for treating or preventing prostaglandin mediated diseases. Pharmaceutical compositions containing such compounds and methods of treatment are also included.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | KR | Republic of Korea | PL | Poland | | |
| CN | China | KZ | Kazakhstan | PT | Portugal | | |
| CU | Cuba | LC | Saint Lucia | RO | Romania | | |
| CZ | Czech Republic | LI | Liechtenstein | RU | Russian Federation | | |
| DE | Germany | LK | Sri Lanka | SD | Sudan | | |
| DK | Denmark | LR | Liberia | SE | Sweden | | |
| EE | Estonia | | | SG | Singapore | | |